ID RET_HUMAN Reviewed; 1114 AA. AC P07949; A8K6Z2; Q15250; Q9BTB0; Q9H4A2; DT 01-AUG-1988, integrated into UniProtKB/Swiss-Prot. DT 01-JUN-1994, sequence version 3. DT 28-JAN-2026, entry version 284. DE RecName: Full=Proto-oncogene tyrosine-protein kinase receptor Ret {ECO:0000305}; DE EC=2.7.10.1 {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; DE AltName: Full=Cadherin family member 12; DE AltName: Full=Proto-oncogene c-Ret {ECO:0000303|PubMed:2660074}; DE Contains: DE RecName: Full=Soluble RET kinase fragment {ECO:0000305|PubMed:21357690}; DE Contains: DE RecName: Full=Extracellular cell-membrane anchored RET cadherin 120 kDa fragment {ECO:0000305|PubMed:21357690}; DE Flags: Precursor; GN Name=RET {ECO:0000303|PubMed:2660074, ECO:0000312|HGNC:HGNC:9967}; GN Synonyms=CDHF12, CDHR16, PTC; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Prostate; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164054; DOI=10.1038/nature02462; RA Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L., RA Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K., RA Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L., RA Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P., RA Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J., RA Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P., RA Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N., RA Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A., RA Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C., RA Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D., RA Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C., RA Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K., RA Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A., RA Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S., RA McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S., RA Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., RA Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., RA Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M., RA Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A., RA Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P., RA Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y., RA Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D., RA Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 10."; RL Nature 429:375-381(2004). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT CYS-982. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-280 (ISOFORMS 1/2). RX PubMed=2660074; RA Takahashi M.; RT "Isolation of ret proto-oncogene cDNA with an amino-terminal signal RT sequence."; RL Oncogene 4:805-806(1989). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] OF 255-1114 (ISOFORM 1). RX PubMed=3078962; RA Takahashi M., Buma Y., Iwamoto T., Inaguma Y., Ikeda H., Hiai H.; RT "Cloning and expression of the ret proto-oncogene encoding a tyrosine RT kinase with two potential transmembrane domains."; RL Oncogene 3:571-578(1988). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 588-1063 (ISOFORM 2), AND CHROMOSOMAL RP TRANSLOCATION WITH TRIM27. RX PubMed=3037315; DOI=10.1128/mcb.7.4.1378-1385.1987; RA Takahashi M., Cooper G.M.; RT "ret transforming gene encodes a fusion protein homologous to tyrosine RT kinases."; RL Mol. Cell. Biol. 7:1378-1385(1987). RN [7] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH GOLGA5. RC TISSUE=Fibroblast; RX PubMed=2734021; RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RT "Activation of the ret-II oncogene without a sequence encoding a RT transmembrane domain and transforming activity of two ret-II oncogene RT products differing in carboxy-termini due to alternative splicing."; RL Oncogene 4:789-794(1989). RN [8] RP ERRATUM OF PUBMED:2734021. RA Ishizaka Y., Ochiai M., Tahira T., Suhimura T., Nahao M.; RL Oncogene 4:1415-1415(1989). RN [9] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-1114 (ISOFORM 1), AND CHROMOSOMAL RP TRANSLOCATION WITH CCDC6. RC TISSUE=Thyroid papillary carcinoma; RX PubMed=2406025; DOI=10.1016/0092-8674(90)90659-3; RA Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., RA Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G.; RT "PTC is a novel rearranged form of the ret proto-oncogene and is frequently RT detected in vivo in human thyroid papillary carcinomas."; RL Cell 60:557-563(1990). RN [10] RP NUCLEOTIDE SEQUENCE [MRNA] OF 713-770 (ISOFORMS 1/2), AND CHROMOSOMAL RP TRANSLOCATION WITH PCM1. RX PubMed=10980597; DOI=10.1038/sj.onc.1203772; RA Corvi R., Berger N., Balczon R., Romeo G.; RT "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma."; RL Oncogene 19:4236-4242(2000). RN [11] RP SUBCELLULAR LOCATION, AND COFACTOR. RX PubMed=9575150; DOI=10.1074/jbc.273.20.12077; RA van Weering D.H., Moen T.C., Braakman I., Baas P.D., Bos J.L.; RT "Expression of the receptor tyrosine kinase Ret on the plasma membrane is RT dependent on calcium."; RL J. Biol. Chem. 273:12077-12081(1998). RN [12] RP CHROMOSOMAL TRANSLOCATION WITH TRIM33 AND TRIM24. RX PubMed=10439047; DOI=10.1038/sj.onc.1202824; RA Klugbauer S., Rabes H.M.; RT "The transcription coactivator HTIF1 and a related protein are fused to the RT RET receptor tyrosine kinase in childhood papillary thyroid carcinomas."; RL Oncogene 18:4388-4393(1999). RN [13] RP PHOSPHORYLATION AT TYR-1015 AND TYR-1062. RX PubMed=11061555; DOI=10.1210/jcem.85.10.6882; RA Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G., RA Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M.; RT "Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and RT ret-derived oncoproteins."; RL J. Clin. Endocrinol. Metab. 85:3898-3907(2000). RN [14] RP COFACTOR, AND MUTAGENESIS OF TYR-36; TYR-41 AND TRP-85. RX PubMed=11445581; DOI=10.1074/jbc.m104968200; RA Anders J., Kjar S., Ibanez C.F.; RT "Molecular modeling of the extracellular domain of the RET receptor RT tyrosine kinase reveals multiple cadherin-like domains and a calcium- RT binding site."; RL J. Biol. Chem. 276:35808-35817(2001). RN [15] RP PHOSPHORYLATION AT TYR-806; TYR-809; TYR-900; TYR-905; TYR-981; TYR-1015; RP TYR-1062; TYR-1090 AND TYR-1096. RX PubMed=14711813; DOI=10.1074/jbc.m312600200; RA Kawamoto Y., Takeda K., Okuno Y., Yamakawa Y., Ito Y., Taguchi R., Kato M., RA Suzuki H., Takahashi M., Nakashima I.; RT "Identification of RET autophosphorylation sites by mass spectrometry."; RL J. Biol. Chem. 279:14213-14224(2004). RN [16] RP CHROMOSOMAL TRANSLOCATION WITH TRIM27. RX PubMed=12787916; DOI=10.1016/s0027-5107(03)00056-3; RA Saenko V., Rogounovitch T., Shimizu-Yoshida Y., Abrosimov A., Lushnikov E., RA Roumiantsev P., Matsumoto N., Nakashima M., Meirmanov S., Ohtsuru A., RA Namba H., Tsyb A., Yamashita S.; RT "Novel tumorigenic rearrangement, Delta rfp/ret, in a papillary thyroid RT carcinoma from externally irradiated patient."; RL Mutat. Res. 527:81-90(2003). RN [17] RP RETRACTED PAPER. RX PubMed=16778204; DOI=10.1158/0008-5472.can-06-0228; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RT "The receptor-type protein tyrosine phosphatase J antagonizes the RT biochemical and biological effects of RET-derived oncoproteins."; RL Cancer Res. 66:6280-6287(2006). RN [18] RP RETRACTION NOTICE OF PUBMED:16778204. RX PubMed=30552125; DOI=10.1158/0008-5472.can-18-3456; RA Iervolino A., Iuliano R., Trapasso F., Viglietto G., Melillo R.M., RA Carlomagno F., Santoro M., Fusco A.; RL Cancer Res. 78:6907-6907(2018). RN [19] RP ACTIVITY REGULATION. RX PubMed=17884497; DOI=10.1016/j.bmcl.2007.07.104; RA Graham Robinett R., Freemerman A.J., Skinner M.A., Shewchuk L., Lackey K.; RT "The discovery of substituted 4-(3-hydroxyanilino)-quinolines as potent RET RT kinase inhibitors."; RL Bioorg. Med. Chem. Lett. 17:5886-5893(2007). RN [20] RP ACTIVITY REGULATION BY SORAFENIB. RX PubMed=17664273; DOI=10.1074/jbc.m703461200; RA Plaza-Menacho I., Mologni L., Sala E., Gambacorti-Passerini C., Magee A.I., RA Links T.P., Hofstra R.M.W., Barford D., Isacke C.M.; RT "Sorafenib functions to potently suppress RET tyrosine kinase activity by RT direct enzymatic inhibition and promoting RET lysosomal degradation RT independent of proteasomal targeting."; RL J. Biol. Chem. 282:29230-29240(2007). RN [21] RP ACTIVITY REGULATION BY 3- AND 4-SUBSTITUTED BETA-CARBOLIN-1-ONES. RX PubMed=19053769; DOI=10.1021/jm8007823; RA Cincinelli R., Cassinelli G., Dallavalle S., Lanzi C., Merlini L., RA Botta M., Tuccinardi T., Martinelli A., Penco S., Zunino F.; RT "Synthesis, modeling, and RET protein kinase inhibitory activity of 3- and RT 4-substituted beta-carbolin-1-ones."; RL J. Med. Chem. 51:7777-7787(2008). RN [22] RP INTERACTION WITH CD2AP, AND MUTAGENESIS OF LYS-758. RX PubMed=18753381; DOI=10.1523/jneurosci.2738-08.2008; RA Tsui C.C., Pierchala B.A.; RT "CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation RT of ret signal transduction."; RL J. Neurosci. 28:8789-8800(2008). RN [23] RP INTERACTION WITH AIP. RX PubMed=19366855; DOI=10.1210/jc.2008-1980; RA Vargiolu M., Fusco D., Kurelac I., Dirnberger D., Baumeister R., Morra I., RA Melcarne A., Rimondini R., Romeo G., Bonora E.; RT "The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon RT receptor-interacting protein to alter survivin availability."; RL J. Clin. Endocrinol. Metab. 94:2571-2578(2009). RN [24] RP INDUCTION BY NKX2-1; PHOX2B; SOX10 AND PAX3. RX PubMed=19853745; DOI=10.1016/j.jpedsurg.2008.11.055; RA Leon T.Y.Y., Ngan E.S.W., Poon H.-C., So M.-T., Lui V.C.H., Tam P.K.H., RA Garcia-Barcelo M.M.; RT "Transcriptional regulation of RET by Nkx2-1, Phox2b, Sox10, and Pax3."; RL J. Pediatr. Surg. 44:1904-1912(2009). RN [25] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [26] RP FUNCTION IN DEVELOPMENT OF MECHANORECEPTORS. RX PubMed=20064382; DOI=10.1016/j.neuron.2009.12.014; RA Ma Q.; RT "RETouching upon mechanoreceptors."; RL Neuron 64:773-776(2009). RN [27] RP ACTIVITY REGULATION, AND REVIEW ON KINASE INHIBITORS. RX PubMed=20605972; DOI=10.1210/er.2009-0031; RA Ye L., Santarpia L., Gagel R.F.; RT "The evolving field of tyrosine kinase inhibitors in the treatment of RT endocrine tumors."; RL Endocr. Rev. 31:578-599(2010). RN [28] RP ACTIVITY REGULATION. RX PubMed=20409618; DOI=10.1016/j.ejmech.2010.03.017; RA Brandt W., Mologni L., Preu L., Lemcke T., Gambacorti-Passerini C., RA Kunick C.; RT "Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- RT thienyl)nicotinonitrile scaffold."; RL Eur. J. Med. Chem. 45:2919-2927(2010). RN [29] RP FUNCTION IN PITUITARY. RX PubMed=20616503; DOI=10.1159/000318502; RA Garcia-Lavandeira M., Diaz-Rodriguez E., Garcia-Rendueles M.E., RA Rodrigues J.S., Perez-Romero S., Bravo S.B., Alvarez C.V.; RT "Functional role of the RET dependence receptor, GFRa co-receptors and RT ligands in the pituitary."; RL Front. Horm. Res. 38:127-138(2010). RN [30] RP FUNCTION IN CELL ADHESION/MIGRATION. RX PubMed=20702524; DOI=10.1210/jc.2010-0771; RA Cockburn J.G., Richardson D.S., Gujral T.S., Mulligan L.M.; RT "RET-mediated cell adhesion and migration require multiple integrin RT subunits."; RL J. Clin. Endocrinol. Metab. 95:E342-E346(2010). RN [31] RP SUBCELLULAR LOCATION. RX PubMed=19823924; DOI=10.1007/s10895-009-0548-x; RA Richardson D.S., Mulligan L.M.; RT "Direct visualization of vesicle maturation and plasma membrane protein RT trafficking."; RL J. Fluoresc. 20:401-405(2010). RN [32] RP ACTIVITY REGULATION. RX PubMed=21134556; DOI=10.1016/j.surg.2010.09.026; RA Samadi A.K., Mukerji R., Shah A., Timmermann B.N., Cohen M.S.; RT "A novel RET inhibitor with potent efficacy against medullary thyroid RT cancer in vivo."; RL Surgery 148:1228-1236(2010). RN [33] RP FUNCTION IN CELL ADHESION, FUNCTION IN APOPTOSIS, PROTEOLYTIC PROCESSING BY RP CASPASE-3 AT ASP-707 AND ASP-1017, MUTAGENESIS OF ASP-707; LYS-758 AND RP 708-ALA--SER-1114, AND SUBUNIT. RX PubMed=21357690; DOI=10.1074/jbc.m110.195461; RA Cabrera J.R., Bouzas-Rodriguez J., Tauszig-Delamasure S., Mehlen P.; RT "RET modulates cell adhesion via its cleavage by caspase in sympathetic RT neurons."; RL J. Biol. Chem. 286:14628-14638(2011). RN [34] RP INTERACTION WITH PTK2/FAK1, AND FUNCTION IN PTK2/FAK1 PHOSPHORYLATION. RX PubMed=21454698; DOI=10.1074/jbc.m110.168500; RA Plaza-Menacho I., Morandi A., Mologni L., Boender P., RA Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P., RA McDonald N.Q., Isacke C.M.; RT "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming RT a direct and reciprocal RET-FAK transactivation mechanism."; RL J. Biol. Chem. 286:17292-17302(2011). RN [35] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=21994944; DOI=10.1074/jbc.m111.246413; RA Geng Z., Xu F.Y., Huang S.H., Chen Z.Y.; RT "Sorting protein-related receptor SorLA controls regulated secretion of RT glial cell line-derived neurotrophic factor."; RL J. Biol. Chem. 286:41871-41882(2011). RN [36] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=23333276; DOI=10.1016/j.celrep.2012.12.011; RA Glerup S., Lume M., Olsen D., Nyengaard J.R., Vaegter C.B., Gustafsen C., RA Christensen E.I., Kjolby M., Hay-Schmidt A., Bender D., Madsen P., RA Saarma M., Nykjaer A., Petersen C.M.; RT "SorLA controls neurotrophic activity by sorting of GDNF and its receptors RT GFRalpha1 and RET."; RL Cell Rep. 3:186-199(2013). RN [37] RP INTERACTION WITH GFRAL, SUBCELLULAR LOCATION, FUNCTION, AND MUTAGENESIS OF RP TYR-1062. RX PubMed=28953886; DOI=10.1038/nature24042; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 550:255-259(2017). RN [38] RP ERRATUM OF PUBMED:28953886. RX PubMed=29144449; DOI=10.1038/nature24481; RA Hsu J.Y., Crawley S., Chen M., Ayupova D.A., Lindhout D.A., Higbee J., RA Kutach A., Joo W., Gao Z., Fu D., To C., Mondal K., Li B., Kekatpure A., RA Wang M., Laird T., Horner G., Chan J., McEntee M., Lopez M., RA Lakshminarasimhan D., White A., Wang S.P., Yao J., Yie J., Matern H., RA Solloway M., Haldankar R., Parsons T., Tang J., Shen W.D., Alice Chen Y., RA Tian H., Allan B.B.; RT "Non-homeostatic body weight regulation through a brainstem-restricted RT receptor for GDF15."; RL Nature 551:398-398(2017). RN [39] RP FUNCTION, AND INTERACTION WITH GFRAL. RX PubMed=28846097; DOI=10.1038/nm.4392; RA Mullican S.E., Lin-Schmidt X., Chin C.N., Chavez J.A., Furman J.L., RA Armstrong A.A., Beck S.C., South V.J., Dinh T.Q., Cash-Mason T.D., RA Cavanaugh C.R., Nelson S., Huang C., Hunter M.J., Rangwala S.M.; RT "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in RT mice and nonhuman primates."; RL Nat. Med. 23:1150-1157(2017). RN [40] RP FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH GFRAL, AND PHOSPHORYLATION RP AT TYR-905 AND TYR-1062. RX PubMed=28846099; DOI=10.1038/nm.4394; RA Yang L., Chang C.C., Sun Z., Madsen D., Zhu H., Padkjaer S.B., Wu X., RA Huang T., Hultman K., Paulsen S.J., Wang J., Bugge A., Frantzen J.B., RA Noergaard P., Jeppesen J.F., Yang Z., Secher A., Chen H., Li X., John L.M., RA Shan B., He Z., Gao X., Su J., Hansen K.T., Yang W., Joergensen S.B.; RT "GFRAL is the receptor for GDF15 and is required for the anti-obesity RT effects of the ligand."; RL Nat. Med. 23:1158-1166(2017). RN [41] RP GLYCOSYLATION AT SER-688. RX PubMed=26237509; DOI=10.1038/nsmb.3063; RA Pathak S., Alonso J., Schimpl M., Rafie K., Blair D.E., Borodkin V.S., RA Albarbarawi O., van Aalten D.M.F.; RT "The active site of O-GlcNAc transferase imposes constraints on substrate RT sequence."; RL Nat. Struct. Mol. Biol. 22:744-750(2015). RN [42] {ECO:0007744|PDB:2IVS, ECO:0007744|PDB:2IVT, ECO:0007744|PDB:2IVU, ECO:0007744|PDB:2IVV} RP X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 705-1013 ALONE AND IN COMPLEX WITH RP INHIBITORS, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION AT RP TYR-900 AND TYR-905. RX PubMed=16928683; DOI=10.1074/jbc.m605604200; RA Knowles P.P., Murray-Rust J., Kjaer S., Scott R.P., Hanrahan S., RA Santoro M., Ibanez C.F., McDonald N.Q.; RT "Structure and chemical inhibition of the RET tyrosine kinase domain."; RL J. Biol. Chem. 281:33577-33587(2006). RN [43] {ECO:0007744|PDB:2X2K, ECO:0007744|PDB:2X2L, ECO:0007744|PDB:2X2M} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP INHIBITORS, ACTIVITY REGULATION, AND PHOSPHORYLATION AT TYR-905. RX PubMed=20117004; DOI=10.1016/j.bmc.2010.01.011; RA Mologni L., Rostagno R., Brussolo S., Knowles P.P., Kjaer S., RA Murray-Rust J., Rosso E., Zambon A., Scapozza L., McDonald N.Q., RA Lucchini V., Gambacorti-Passerini C.; RT "Synthesis, structure-activity relationship and crystallographic studies of RT 3-substituted indolin-2-one RET inhibitors."; RL Bioorg. Med. Chem. 18:1482-1496(2010). RN [44] {ECO:0007744|PDB:2X2U} RP X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 29-270, GLYCOSYLATION AT ASN-151, RP AND DISULFIDE BONDS. RX PubMed=20473317; DOI=10.1038/nsmb.1808; RA Kjaer S., Hanrahan S., Totty N., McDonald N.Q.; RT "Mammal-restricted elements predispose human RET to folding impairment by RT HSCR mutations."; RL Nat. Struct. Mol. Biol. 17:726-731(2010). RN [45] {ECO:0007744|PDB:4UX8} RP STRUCTURE BY ELECTRON MICROSCOPY (24.00 ANGSTROMS) OF 29-635 IN COMPLEX RP WITH GFRA1; GDNF AND CALCIUM, FUNCTION, COFACTOR, AND DISULFIDE BONDS. RX PubMed=25242331; DOI=10.1016/j.celrep.2014.08.040; RA Goodman K.M., Kjaer S., Beuron F., Knowles P.P., Nawrotek A., Burns E.M., RA Purkiss A.G., George R., Santoro M., Morris E.P., McDonald N.Q.; RT "RET recognition of GDNF-GFRalpha1 ligand by a composite binding site RT promotes membrane-proximal self-association."; RL Cell Rep. 8:1894-1904(2014). RN [46] {ECO:0007744|PDB:4CKI, ECO:0007744|PDB:4CKJ} RP X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 705-1013 IN COMPLEX WITH RP ADENOSINE, FUNCTION, CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-687; RP TYR-826; TYR-900; TYR-905; TYR-981; TYR-1015; TYR-1029 AND TYR-1062, RP MUTAGENESIS OF GLU-734; LYS-758; ARG-912 AND ILE-913, VARIANT MEN2B RP THR-918, CHARACTERIZATION OF VARIANT MEN2B THR-918, VARIANT MTC MET-804, RP AND CHARACTERIZATION OF VARIANT MTC MET-804. RX PubMed=24560924; DOI=10.1016/j.molcel.2014.01.015; RA Plaza-Menacho I., Barnouin K., Goodman K., Martinez-Torres R.J., Borg A., RA Murray-Rust J., Mouilleron S., Knowles P., McDonald N.Q.; RT "Oncogenic RET kinase domain mutations perturb the autophosphorylation RT trajectory by enhancing substrate presentation in trans."; RL Mol. Cell 53:738-751(2014). RN [47] {ECO:0007744|PDB:6NE7, ECO:0007744|PDB:6NEC, ECO:0007744|PDB:6NJA} RP X-RAY CRYSTALLOGRAPHY (1.87 ANGSTROMS) OF 705-1013, FUNCTION, ACTIVITY RP REGULATION, VARIANT MTC VAL-881, CHARACTERIZATION OF VARIANT MTC VAL-881, RP VARIANT ALA-810, AND CHARACTERIZATION OF VARIANT ALA-810. RX PubMed=31118272; DOI=10.1074/jbc.ra119.007682; RA Terzyan S.S., Shen T., Liu X., Huang Q., Teng P., Zhou M., Hilberg F., RA Cai J., Mooers B.H.M., Wu J.; RT "Structural basis of resistance of mutant RET protein-tyrosine kinase to RT its inhibitors nintedanib and vandetanib."; RL J. Biol. Chem. 294:10428-10437(2019). RN [48] {ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S} RP STRUCTURE BY ELECTRON MICROSCOPY (3.65 ANGSTROMS) OF 29-635 IN COMPLEX WITH RP CALCIUM; GDF15; GFRAL; GFRA1; GFRA2; GFRA3; GDNF; NRTN AND ARTN, COFACTOR, RP AND DISULFIDE BONDS. RX PubMed=31535977; DOI=10.7554/elife.47650; RA Li J., Shang G., Chen Y.J., Brautigam C.A., Liou J., Zhang X., Bai X.C.; RT "Cryo-EM analyses reveal the common mechanism and diversification in the RT activation of RET by different ligands."; RL Elife 8:0-0(2019). RN [49] RP REVIEW ON HSCR VARIANTS. RX PubMed=9359036; RA Hofstra R.M.W., Osinga J., Buys C.H.C.M.; RT "Mutations in Hirschsprung disease: when does a mutation contribute to the RT phenotype."; RL Eur. J. Hum. Genet. 5:180-185(1997). RN [50] RP VARIANTS MEN2A/MTC TYR-611; PHE-618; GLY-620 AND PHE-630. RX PubMed=9067749; RX DOI=10.1002/(sici)1098-1004(1997)9:2<97::aid-humu1>3.0.co;2-m; RA Eng C., Mulligan L.M.; RT "Mutations of the RET proto-oncogene in the multiple endocrine neoplasia RT type 2 syndromes, related sporadic tumours, and Hirschsprung disease."; RL Hum. Mutat. 9:97-109(1997). RN [51] RP VARIANTS MEN2A/MTC TRP-611; SER-618; TYR-618; ARG-620; TYR-620 AND ARG-634. RX PubMed=8103403; DOI=10.1093/hmg/2.7.851; RA Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., RA Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Jr.; RT "Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC."; RL Hum. Mol. Genet. 2:851-856(1993). RN [52] RP VARIANTS MEN2A GLY-618; 632-GLU--CYS-634 DELINS ASP-VAL-ARG; GLY-634; RP PHE-634; TYR-634 AND SER-634. RX PubMed=8099202; DOI=10.1038/363458a0; RA Mulligan L.M., Kwok J.B.J., Healey C.S., Elsdon M.J., Eng C., Gardner E., RA Love D.R., Mole S.E., Moore J.K., Papi L., Ponder M.A., Telenius H., RA Tunnacliffe A., Ponder B.A.J.; RT "Germ-line mutations of the RET proto-oncogene in multiple endocrine RT neoplasia type 2A."; RL Nature 363:458-460(1993). RN [53] RP VARIANTS HSCR1 PRO-40; LEU-399; GLN-762; PRO-765; GLN-897; GLY-972 AND RP LEU-973. RX PubMed=7704557; DOI=10.1159/000472371; RA Yin L., Barone V., Seri M., Bolino A., Bocciardi R., Ceccherini I., RA Pasini B., Tocco T., Lerone M., Cywes S., Moore S., Vanderwinden J.-M., RA Abramowicz M.J., Kristoffersson U., Larsson L.T., Hamel B.C.J., Silengo M., RA Martucciello G., Romeo G.; RT "Heterogeneity and low detection rate of RET mutations in Hirschsprung RT disease."; RL Eur. J. Hum. Genet. 2:272-280(1994). RN [54] RP VARIANT MEN2B THR-918. RX PubMed=7911697; DOI=10.1093/hmg/3.2.237; RA Eng C., Smith D.P., Mulligan L.M., Nagai M.A., Healey C.S., Ponder M.A., RA Gardner E., Scheumann G.F., Jackson C.E., Tunnacliffe A., Ponder B.A.J.; RT "Point mutation within the tyrosine kinase domain of the RET proto-oncogene RT in multiple endocrine neoplasia type 2B and related sporadic tumours."; RL Hum. Mol. Genet. 3:237-241(1994). RN [55] RP VARIANTS MEN2A/MTC ARG-618; SER-618; PHE-620; ARG-620; PHE-634; GLY-634 AND RP TYR-634. RX PubMed=7915165; DOI=10.1093/hmg/3.4.635; RA Xue F., Yu H., Maurer L.H., Memoli V.A., Nutile-Mcmenemy N., Schuster M.K., RA Browden D.W., Mao J.-I., Noll W.W.; RT "Germline RET mutations in MEN 2A and FMTC and their detection by simple RT DNA diagnostic tests."; RL Hum. Mol. Genet. 3:635-638(1994). RN [56] RP VARIANTS MTC/MEN2A TYR-609; ARG-618; SER-618 AND SER-620. RX PubMed=7849720; DOI=10.1093/hmg/3.10.1895; RA Blaugrund J.E., Johns M.M. Jr., Eby Y.J., Ball D.W., Baylin S.B., RA Hruban R.H., Sidransky D.; RT "RET proto-oncogene mutations in inherited and sporadic medullary thyroid RT cancer."; RL Hum. Mol. Genet. 3:1895-1897(1994). RN [57] RP VARIANTS MTC, AND VARIANTS MEN2A. RX PubMed=7874109; DOI=10.1093/hmg/3.11.1939; RA Schuffenecker I., Billaud M., Calender A., Chambe B., Ginet N., RA Calmettes C., Modigliani E., Lenoir G.M.; RT "RET proto-oncogene mutations in French MEN 2A and FMTC families."; RL Hum. Mol. Genet. 3:1939-1943(1994). RN [58] RP VARIANTS HSCR1 TRP-609; ARG-618 AND ARG-620, VARIANT MEN2A ARG-618, AND RP VARIANT MTC ARG-620. RX PubMed=7881414; DOI=10.1093/hmg/3.12.2163; RA Mulligan L.M., Eng C., Attie T., Lyonnet S., Marsh D.J., Hyland V.J., RA Robinson B.G., Frilling A., Verellen-Dumoulin C., Safar A., Venter D.J., RA Munnich A., Ponder B.A.J.; RT "Diverse phenotypes associated with exon 10 mutations of the RET proto- RT oncogene."; RL Hum. Mol. Genet. 3:2163-2167(1994). RN [59] RP VARIANT HSCR1 LYS-921. RX PubMed=7997019; DOI=10.1016/s0140-6736(94)92908-4; RA Pelet A., Attie T., Goulet O., Eng C., Ponder B.A., Munnich A., Lyonnet S.; RT "De-novo mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Lancet 344:1769-1770(1994). RN [60] RP VARIANT MEN2B THR-918. RX PubMed=7906866; DOI=10.1038/367375a0; RA Hofstra R.M.W., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., RA Luo Y., Pasini B., Hoeppener J.W.M., Ploos van Amstel H.K., Romeo G., RA Lips C.J.M., Buys C.H.C.M.; RT "A mutation in the RET proto-oncogene associated with multiple endocrine RT neoplasia type 2B and sporadic medullary thyroid carcinoma."; RL Nature 367:375-376(1994). RN [61] RP VARIANTS HSCR1 PRO-765; GLN-897 AND GLY-972. RX PubMed=8114938; DOI=10.1038/367377a0; RA Romeo G., Ronchetto P., Luo Y., Barone V., Seri M., Ceccherini I., RA Pasini B., Bocciardi R., Lerone M., Kaarlainen H., Martucciello G.; RT "Point mutations affecting the tyrosine kinase domain of the RET proto- RT oncogene in Hirschsprung's disease."; RL Nature 367:377-378(1994). RN [62] RP VARIANTS HSCR1 LEU-32; LEU-64; GLN-330 AND LEU-393. RX PubMed=8114939; DOI=10.1038/367378a0; RA Edery P., Lyonnet S., Mulligan L.M., Pelet A., Dow E., Abel L., Holder S., RA Nihoul-Fkete C., Ponder B.A.J., Munnich A.; RT "Mutations of the RET proto-oncogene in Hirschsprung's disease."; RL Nature 367:378-380(1994). RN [63] RP VARIANT MEN2B THR-918. RX PubMed=7906417; DOI=10.1073/pnas.91.4.1579; RA Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., RA Wells S.A. Jr., Goodfellow P.J., Donis-Keller H.; RT "Single missense mutation in the tyrosine kinase catalytic domain of the RT RET protooncogene is associated with multiple endocrine neoplasia type RT 2B."; RL Proc. Natl. Acad. Sci. U.S.A. 91:1579-1583(1994). RN [64] RP VARIANTS MTC; MEN2A AND MEN2B. RX PubMed=8625130; RX DOI=10.1002/1097-0142(19950801)76:3<479::aid-cncr2820760319>3.0.co;2-m; RA Komminoth P., Kunz E.K., Matias-Guiu X., Hiort O., Christiansen G., RA Colomer A., Roth J., Heitz P.U.; RT "Analysis of RET protooncogene point mutations distinguishes heritable from RT nonheritable medullary thyroid carcinomas."; RL Cancer 76:479-489(1995). RN [65] RP VARIANTS MEN2A SER-618; SER-620; ARG-634 AND TYR-634. RX PubMed=7860065; DOI=10.1007/bf00209399; RA Takiguchi-Shirahama S., Koyama K., Miyauchi A., Wakasugi T., Oishi S., RA Takami H., Hikiji K., Nakamura Y.; RT "Germline mutations of the RET proto-oncogene in eight Japanese patients RT with multiple endocrine neoplasia type 2A (MEN2A)."; RL Hum. Genet. 95:187-190(1995). RN [66] RP VARIANTS HSCR1 LEU-20; SER-93; GLN-330; TYR-609 AND ARG-620, AND VARIANT RP CYS-982. RC TISSUE=Blood; RX PubMed=7633441; DOI=10.1093/hmg/4.5.821; RA Angrist M., Bolk S., Thiel B., Puffenberger E.G., Hofstra R.M.W., RA Buys C.H.C.M., Cass D.T., Chakravarti A.; RT "Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung RT disease."; RL Hum. Mol. Genet. 4:821-830(1995). RN [67] RP VARIANTS HSCR1 HIS-231 AND LYS-251. RC TISSUE=Leukocyte; RX PubMed=7581377; DOI=10.1093/hmg/4.8.1381; RA Attie T., Pelet A., Edery P., Eng C., Mulligan L.M., Amiel J., Boutrand L., RA Beldjord C., Nihoul-Fekete C., Munnich A., Ponder B.A.J., Lyonnet S.; RT "Diversity of RET proto-oncogene mutations in familial and sporadic RT Hirschsprung disease."; RL Hum. Mol. Genet. 4:1381-1386(1995). RN [68] RP VARIANT MEN2B THR-918, AND VARIANT TYR-922. RX PubMed=8595427; DOI=10.1093/hmg/4.10.1987; RA Kitamura Y., Scavarda N., Wells S.A. Jr., Jackson C.E., Goodfellow P.J.; RT "Two maternally derived missense mutations in the tyrosine kinase domain of RT the RET protooncogene in a patient with de novo MEN 2B."; RL Hum. Mol. Genet. 4:1987-1988(1995). RN [69] RP VARIANT MTC ASP-768. RX PubMed=7845675; RA Eng C., Smith D.P., Mulligan L.M., Healey C.S., Zvelebil M.J., RA Stonehouse T.J., Ponder M.A., Jackson C.E., Waterfield M.D., Ponder B.A.J.; RT "A novel point mutation in the tyrosine kinase domain of the RET proto- RT oncogene in sporadic medullary thyroid carcinoma and in a family with RT FMTC."; RL Oncogene 10:509-513(1995). RN [70] RP VARIANTS MTC ASP-768 AND LEU-804. RX PubMed=7784092; RA Bolino A., Schuffenecker I., Luo Y., Seri M., Silengo M., Tocco T., RA Chabrier G., Houdent C., Murat A., Schlumberger M., Tournaire J., RA Lenoir G.M., Romeo G.; RT "RET mutations in exons 13 and 14 of FMTC patients."; RL Oncogene 10:2415-2419(1995). RN [71] RP VARIANTS HSCR1 TYR-157; LYS-359; TYR-609; ARG-620; ASN-1059 DEL AND RP PRO-1061. RA Hofstra R.M.W., Osinga J., Stulp R.P., Scheffer H., Meijers C., RA Buys C.H.C.M.; RT "Mutations in three genes are found associated with the development of RT Hirschsprung disease: RET, EDNRB and EDN3."; RL Am. J. Hum. Genet. 59:A263-A263(1996). RN [72] RP VARIANTS HSCR1 PRO-40 AND PRO-765. RX PubMed=9043870; DOI=10.1159/000472232; RA Yin L., Seri M., Barone V., Tocco T., Scaranari M., Romeo G.; RT "Prevalence and parental origin of de novo RET mutations in Hirschsprung's RT disease."; RL Eur. J. Hum. Genet. 4:356-358(1996). RN [73] RP VARIANTS MTC/MEN2A. RX PubMed=8557249; DOI=10.1007/bf00218825; RA Landsvater R.M., Jansen R.P.M., Hofstra R.M.W., Buys C.H.C.M., Lips C.J.M., RA van Amstel H.K.P.; RT "Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, RT MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A."; RL Hum. Genet. 97:11-14(1996). RN [74] RP VARIANT MTC ASP-768, VARIANTS MEN2A ARG-609; GLY-609; SER-611 AND ARG-611, RP AND VARIANT MEN2B THR-918. RX PubMed=8807338; RX DOI=10.1002/(sici)1098-1004(1996)8:1<64::aid-humu9>3.0.co;2-p; RA Kambouris M., Jackson C.E., Feldman G.L.; RT "Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial RT medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses RT of RET proto-oncogene mutations."; RL Hum. Mutat. 8:64-70(1996). RN [75] RP VARIANTS MEN2A. RX PubMed=8626834; DOI=10.1210/jcem.81.5.8626834; RA Frank-Raue K., Hoeppner W., Frilling A., Kotzerke J., Dralle H., Haase R., RA Mann K., Seif F., Kirchner R., Rendl J., Deckart H.F., Ritter M.M., RA Hampel R., Klempa J., Scholz G.H., Raue F., Bogner U., Brabant G., RA Grussendorf M., Hartenstein C.H., Heidemann P., Hensen J., Doerr A.G., RA Hoehne T., Hoernig-Franz I., Huefner M., Kress J., Langer H.J., RA Lottermoser K., Schweikert H.U., Kusterer K., Menken U., Mercier J., RA Oelkers W., Sauer J., Simon D., Starrach G., Ziegler R.; RT "Mutations of the ret protooncogene in German multiple endocrine neoplasia RT families: relation between genotype and phenotype."; RL J. Clin. Endocrinol. Metab. 81:1780-1783(1996). RN [76] RP VARIANT HSCR1 LEU-893. RX PubMed=9174404; DOI=10.1002/bies.950190506; RA Edery P., Eng C., Munnich A., Lyonnet S.; RT "RET in human development and oncogenesis."; RL Bioessays 19:389-395(1997). RN [77] RP VARIANT MEN2A HIS-GLU-LEU-CYS-634 INS. RX PubMed=9097963; DOI=10.1093/hmg/6.4.587; RA Hoeppner W., Ritter M.M.; RT "A duplication of 12 bp in the critical cysteine rich domain of the RET RT proto-oncogene results in a distinct phenotype of multiple endocrine RT neoplasia type 2A."; RL Hum. Mol. Genet. 6:587-590(1997). RN [78] RP VARIANTS HSCR1 PRO-180; GLN-313; ARG-620 AND PHE-791. RX PubMed=9090527; RX DOI=10.1002/(sici)1098-1004(1997)9:3<243::aid-humu5>3.0.co;2-8; RA Seri M., Yin L., Barone V., Bolino A., Celli I., Bocciardi R., Pasini B., RA Ceccherini I., Lerone M., Kristoffersson U., Larsson L.T., Casasa J.M., RA Cass D.T., Abramowicz M.J., Vanderwinden J.-M., Kravcenkiene I., Baric I., RA Silengo M., Martucciello G., Romeo G.; RT "Frequency of RET mutations in long- and short-segment Hirschsprung RT disease."; RL Hum. Mutat. 9:243-249(1997). RN [79] RP VARIANT MTC ARG-618, AND VARIANT HSCR1 ARG-618. RX PubMed=9259198; RX DOI=10.1002/(sici)1098-1004(1997)10:2<155::aid-humu7>3.0.co;2-j; RA Peretz H., Luboshitsky R., Baron E., Biton A., Gershoni R., Usher S., RA Grynberg E., Yakobson E., Graff E., Lapidot M.; RT "Cys 618 Arg mutation in the RET proto-oncogene associated with familial RT medullary thyroid carcinoma and maternally transmitted Hirschsprung's RT disease suggesting a role for imprinting."; RL Hum. Mutat. 10:155-159(1997). RN [80] RP VARIANT MEN2B PHE-883. RC TISSUE=Peripheral blood leukocyte; RX PubMed=9360560; DOI=10.1210/jcem.82.11.4508; RA Gimm O., Marsh D.J., Andrew S.D., Frilling A., Dahia P.L.M., Mulligan L.M., RA Zajac J.D., Robinson B.G., Eng C.; RT "Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in RT multiple endocrine neoplasia type 2B without codon 918 mutation."; RL J. Clin. Endocrinol. Metab. 82:3902-3904(1997). RN [81] RP VARIANT MTC ALA-891. RX PubMed=9398735; DOI=10.1210/jcem.82.12.4439; RA Hofstra R.M.W., Fattoruso O., Quadro L., Wu Y., Libroia A., Verga U., RA Colantuoni V., Buys C.H.C.M.; RT "A novel point mutation in the intracellular domain of the ret RT protooncogene in a family with medullary thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 82:4176-4178(1997). RN [82] RP VARIANTS HSCR1 SER-174 AND TYR-197. RX PubMed=9094028; DOI=10.1016/s0022-3468(97)90616-3; RA Kusafuka T., Wang Y., Puri P.; RT "Mutation analysis of the RET, the endothelin-B receptor, and the RT endothelin-3 genes in sporadic cases of Hirschsprung's disease."; RL J. Pediatr. Surg. 32:501-504(1997). RN [83] RP VARIANTS MTC TYR-630 AND SER-630, AND VARIANT SER-691. RX PubMed=9223675; DOI=10.1038/sj.onc.1201102; RA Kitamura Y., Goodfellow P.J., Shimizu K., Nagahama M., Ito K., Kitagawa W., RA Akasu H., Takami H., Tanaka S., Wells S.A. Jr.; RT "Novel germline RET proto-oncogene mutations associated with medullary RT thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC."; RL Oncogene 14:3103-3106(1997). RN [84] RP VARIANT MEN2B PHE-883. RX PubMed=9294615; DOI=10.1038/sj.onc.1201481; RA Smith D.P., Houghton C., Ponder B.A.J.; RT "Germline mutation of RET codon 883 in two cases of de novo MEN 2B."; RL Oncogene 15:1213-1217(1997). RN [85] RP VARIANT HSCR1 LEU-1039, AND VARIANT SER-691. RX PubMed=9497256; DOI=10.1086/301759; RA Amiel J., Salomon R., Attie T., Pelet A., Trang H., Mokhtari M., RA Gaultier C., Munnich A., Lyonnet S.; RT "Mutations of the RET-GDNF signaling pathway in Ondine's curse."; RL Am. J. Hum. Genet. 62:715-717(1998). RN [86] RP VARIANT MTC GLY-611. RX PubMed=9677065; RX DOI=10.1002/(sici)1096-8628(19980707)78:3<271::aid-ajmg13>3.0.co;2-c; RA Oriola J., Paramo C., Halperin I., Garcia-Mayor R.V., Rivera-Fillat F.; RT "Novel point mutation in exon 10 of the RET proto-oncogene in a family with RT medullary thyroid carcinoma."; RL Am. J. Med. Genet. 78:271-273(1998). RN [87] RP VARIANT CYS-982. RX PubMed=9760196; DOI=10.1007/s004390050797; RA Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.; RT "Phenotypic variation in a family with mutations in two Hirschsprung- RT related genes (RET and endothelin receptor B)."; RL Hum. Genet. 103:145-148(1998). RN [88] RP VARIANTS MEN2A TYR-609; SER-618; ARG-620 AND TRP-620, AND VARIANTS HSCR1 RP TYR-609; SER-618; ARG-620 AND TRP-620. RX PubMed=9384613; DOI=10.1093/hmg/7.1.129; RA Decker R.A., Peacock M.L., Watson P.; RT "Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 RT genotypes and strong genotype-phenotype correlation."; RL Hum. Mol. Genet. 7:129-134(1998). RN [89] RP VARIANT MEN2A CYS-ARG-THR-636 INS. RX PubMed=9452064; DOI=10.1002/humu.1380110143; RA Hoeppner W., Dralle H., Brabant G.; RT "Duplication of 9 base pairs in the critical cysteine-rich domain of the RT RET proto-oncogene causes multiple endocrine neoplasia type 2A."; RL Hum. Mutat. Suppl. 1:S128-S130(1998). RN [90] RP VARIANT MTC MET-804. RX PubMed=9452077; DOI=10.1002/humu.1380110156; RA Fattoruso O., Quadro L., Libroia A., Verga U., Lupoli G., Cascone E., RA Colantuoni V.; RT "A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET RT proto-oncogene in two families affected by familial medullary thyroid RT carcinoma."; RL Hum. Mutat. Suppl. 1:S167-S171(1998). RN [91] RP VARIANTS MTC/MEN2A PHE-790 AND PHE-791. RX PubMed=9506724; DOI=10.1210/jcem.83.3.4619; RA Berndt I., Reuter M., Saller B., Frank-Raue K., Groth P., Grussendorf M., RA Raue F., Ritter M.M., Hoeppner W.; RT "A new hot spot for mutations in the ret protooncogene causing familial RT medullary thyroid carcinoma and multiple endocrine neoplasia type 2A."; RL J. Clin. Endocrinol. Metab. 83:770-774(1998). RN [92] RP VARIANTS MTC AND MEN2A. RX PubMed=9621513; DOI=10.1007/s100380050048; RA Shirahama S., Ogura K., Takami H., Ito K., Tohsen T., Miyauchi A., RA Nakamura Y.; RT "Mutational analysis of the RET proto-oncogene in 71 Japanese patients with RT medullary thyroid carcinoma."; RL J. Hum. Genet. 43:101-106(1998). RN [93] RP VARIANTS HSCR1 LYS-626 AND GLN-813. RX PubMed=10090908; DOI=10.1086/302329; RA Auricchio A., Griseri P., Carpentieri M.L., Betsos N., Staiano A., RA Tozzi A., Priolo M., Thompson H., Bocciardi R., Romeo G., Ballabio A., RA Ceccherini I.; RT "Double heterozygosity for a RET substitution interfering with splicing and RT an EDNRB missense mutation in Hirschsprung disease."; RL Am. J. Hum. Genet. 64:1216-1221(1999). RN [94] RP VARIANTS HSCR1 ASN-1059 DEL AND PRO-1061. RX PubMed=10484767; DOI=10.1093/hmg/8.11.1989; RA Geneste O., Bidaud C., De Vita G., Hofstra R.M.W., Tartare-Deckert S., RA Buys C.H.C.M., Lenoir G.M., Santoro M., Billaud M.; RT "Two distinct mutations of the RET receptor causing Hirschsprung's disease RT impair the binding of signalling effectors to a multifunctional docking RT site."; RL Hum. Mol. Genet. 8:1989-1999(1999). RN [95] RP VARIANT MTC GLU-GLU-CYS-531 INS. RX PubMed=10323403; DOI=10.1210/jcem.84.5.5665; RA Pigny P., Bauters C., Wemeau J.-L., Houcke M.L., Crepin M., Caron P., RA Giraud S., Calender A., Buisine M.-P., Kerckaert J.-P., Porchet N.; RT "A novel 9-base pair duplication in RET exon 8 in familial medullary RT thyroid carcinoma."; RL J. Clin. Endocrinol. Metab. 84:1700-1704(1999). RN [96] RP VARIANT MEN2A GLY-640. RX PubMed=10522989; DOI=10.1210/jcem.84.10.6056; RA Tessitore A., Sinisi A.A., Pasquali D., Cardone M., Vitale D., RA Bellastella A., Colantuoni V.; RT "A novel case of multiple endocrine neoplasia type 2A associated with two RT de novo mutations of the RET protooncogene."; RL J. Clin. Endocrinol. Metab. 84:3522-3527(1999). RN [97] RP VARIANTS HSCR1 GLN-287; PRO-690; ARG-767 AND GLN-873. RX PubMed=10664228; DOI=10.1007/s004310050043; RA Sakai T., Nirasawa Y., Itoh Y., Wakizaka A.; RT "Japanese patients with sporadic Hirschsprung: mutation analysis of the RT receptor tyrosine kinase proto-oncogene, endothelin-B receptor, endothelin- RT 3, glial cell line-derived neurotrophic factor and neurturin genes: a RT comparison with similar studies."; RL Eur. J. Pediatr. 159:160-167(2000). RN [98] RP VARIANTS MTC MET-804 AND LEU-844. RX PubMed=10826520; DOI=10.1055/s-2000-5806; RA Bartsch D.K., Hasse C., Schug C., Barth P., Rothmund M., Hoeppner W.; RT "A RET double mutation in the germline of a kindred with FMTC."; RL Exp. Clin. Endocrinol. Diabetes 108:128-132(2000). RN [99] RP VARIANT GLN-600. RX PubMed=10612852; RX DOI=10.1002/(sici)1098-1004(200001)15:1<122::aid-humu41>3.0.co;2-7; RA Saez M.E., Ruiz A., Cebrian A., Morales F., Robledo M., Antinolo G., RA Borrego S.; RT "A new germline mutation, R600Q, within the coding region of RET proto- RT oncogene: a rare polymorphism or a MEN 2 causing mutation?"; RL Hum. Mutat. 15:122-122(2000). RN [100] RP VARIANT HSCR1 GLU-907. RX PubMed=10790203; RX DOI=10.1002/(sici)1098-1004(200005)15:5<418::aid-humu3>3.0.co;2-2; RA Hofstra R.M., Wu Y., Stulp R.P., Elfferich P., Osinga J., Maas S.M., RA Siderius L., Brooks A.S., vd Ende J.J., Heydendael V.M., Severijnen R.S., RA Bax K.M., Meijers C., Buys C.H.; RT "RET and GDNF gene scanning in Hirschsprung patients using two dual RT denaturing gel systems."; RL Hum. Mutat. 15:418-429(2000). RN [101] RP VARIANTS HSCR1 LEU-32; CYS-77; TRP-360 AND LYS-394. RX PubMed=10618407; DOI=10.1073/pnas.97.1.268; RA Bolk S., Pelet A., Hofstra R.M.W., Angrist M., Salomon R., Croaker D., RA Buys C.H.C.M., Lyonnet S., Chakravarti A.; RT "A human model for multigenic inheritance: phenotypic expression in RT Hirschsprung disease requires both the RET gene and a new 9q31 locus."; RL Proc. Natl. Acad. Sci. U.S.A. 97:268-273(2000). RN [102] RP VARIANTS MTC GLY-639; GLY-641 AND PHE-922. RX PubMed=11692159; DOI=10.1007/s001090100250; RA Kalinin V.N., Amosenko F.A., Shabanov M.A., Lubchenko L.N., Hosch S.B., RA Garkavtseva R.F., Izbicki J.R.; RT "Three novel mutations in the RET proto-oncogene."; RL J. Mol. Med. 79:609-612(2001). RN [103] RP VARIANTS PHEOCHROMOCYTOMA ARG-634; GLY-634; TYR-634; SER-634; PHE-634; RP TRP-634 AND PHE-791. RX PubMed=12000816; DOI=10.1056/nejmoa020152; RG The Freiburg-Warsaw-Columbus pheochromocytoma study group; RA Neumann H.P.H., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., RA Schipper J., Klisch J., Altehoefer C., Zerres K., Januszewicz A., RA Smith W.M., Munk R., Manz T., Glaesker S., Apel T.W., Treier M., RA Reineke M., Walz M.K., Hoang-Vu C., Brauckhoff M., Klein-Franke A., RA Klose P., Schmidt H., Maier-Woelfle M., Peczkowska M., Szmigielski C., RA Eng C.; RT "Germ-line mutations in nonsyndromic pheochromocytoma."; RL N. Engl. J. Med. 346:1459-1466(2002). RN [104] RP VARIANT HIS-114. RX PubMed=12086152; DOI=10.1620/tjem.196.241; RA Kanai M., Numakura C., Sasaki A., Shirahata E., Akaba K., Hashimoto M., RA Hasegawa H., Shirasawa S., Hayasaka K.; RT "Congenital central hypoventilation syndrome: a novel mutation of the RET RT gene in an isolated case."; RL Tohoku J. Exp. Med. 196:241-246(2002). RN [105] RP VARIANTS HIS-67; HIS-114; GLU-432; ASN-489; SER-691 AND CYS-982. RX PubMed=14566559; DOI=10.1007/s00439-003-1036-z; RA Sasaki A., Kanai M., Kijima K., Akaba K., Hashimoto M., Hasegawa H., RA Otaki S., Koizumi T., Kusuda S., Ogawa Y., Tuchiya K., Yamamoto W., RA Nakamura T., Hayasaka K.; RT "Molecular analysis of congenital central hypoventilation syndrome."; RL Hum. Genet. 114:22-26(2003). RN [106] RP VARIANTS [LARGE SCALE ANALYSIS] GLY-145; TRP-360 AND GLU-593. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [107] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-163; ASN-278; MET-292; ASN-489; RP SER-691; THR-749; SER-826; LEU-844; CYS-982 AND TYR-1112. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [108] RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; THR-918; LEU-1049 AND RP SER-1067, POSSIBLE INVOLVEMENT IN RENAL AGENESIS, AND CHARACTERIZATION OF RP VARIANTS THR-198; ALA-376; HIS-394; ILE-778; SER-894; LEU-1049 AND RP SER-1067. RX PubMed=18252215; DOI=10.1016/j.ajhg.2007.10.008; RA Skinner M.A., Safford S.D., Reeves J.G., Jackson M.E., Freemerman A.J.; RT "Renal aplasia in humans is associated with RET mutations."; RL Am. J. Hum. Genet. 82:344-351(2008). RN [109] RP VARIANTS HSCR1 549-LYS-GLY-550 DEL; CYS-114; GLY-145; LEU-155; PRO-175; RP ALA-278; PRO-278; ASN-300; GLN-313; ILE-316; LEU-339; TYR-353; GLN-360; RP MET-397; MET-412; ARG-423; LYS-480; GLN-595; LEU-679; GLN-694; SER-783; RP ARG-830; THR-907; LEU-961; VAL-1052; CYS-1062 AND THR-1064, AND VARIANTS RP HIS-114; ASN-278 AND MET-292. RX PubMed=22174939; DOI=10.1371/journal.pone.0028986; RA So M.T., Leon T.Y., Cheng G., Tang C.S., Miao X.P., Cornes B.K., Diem N.N., RA Cui L., Ngan E.S., Lui V.C., Wu X.Z., Wang B., Wang H., Yuan Z.W., RA Huang L.M., Li L., Xia H., Zhu D., Liu J., Nguyen T.L., Chan I.H., RA Chung P.H., Liu X.L., Zhang R., Wong K.K., Sham P.C., Cherny S.S., RA Tam P.K., Garcia-Barcelo M.M.; RT "RET mutational spectrum in Hirschsprung disease: evaluation of 601 Chinese RT patients."; RL PLoS ONE 6:E28986-E28986(2011). RN [110] RP ACTIVITY REGULATION, VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; RP VAL-807; ALA-810; SER-810; ILE-871 AND VAL-998, CHARACTERIZATION OF RP VARIANTS ILE-730; VAL-730; LYS-732; ALA-738; ASN-806; VAL-807; ALA-810; RP SER-810; ILE-871 AND VAL-998, VARIANTS MTC LEU-804; MET-804 AND THR-918, RP AND CHARACTERIZATION OF VARIANTS MTC LEU-804; MET-804 AND THR-918. RX PubMed=29908090; DOI=10.1111/bph.14395; RA Liu X., Shen T., Mooers B.H.M., Hilberg F., Wu J.; RT "Drug resistance profiles of mutations in the RET kinase domain."; RL Br. J. Pharmacol. 175:3504-3515(2018). CC -!- FUNCTION: Receptor tyrosine-protein kinase involved in numerous CC cellular mechanisms including cell proliferation, neuronal navigation, CC cell migration, and cell differentiation in response to glia cell line- CC derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) CC (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, CC PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, CC PubMed:28953886, PubMed:31118272). In contrast to most receptor CC tyrosine kinases, RET requires not only its cognate ligands but also CC coreceptors, for activation (PubMed:21994944, PubMed:23333276, CC PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, CC NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR CC coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), CC triggering RET autophosphorylation and activation, leading to CC activation of downstream signaling pathways, including the MAPK- and CC AKT-signaling pathways (PubMed:21994944, PubMed:23333276, CC PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, CC PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 CC signaling: in the presence of the ligand GDNF in somatotrophs within CC pituitary, promotes survival and down regulates growth hormone (GH) CC production, but triggers apoptosis in absence of GDNF (PubMed:20616503, CC PubMed:21994944). Required for the molecular mechanisms orchestration CC during intestine organogenesis via the ARTN-GFRA3 signaling: involved CC in the development of enteric nervous system and renal organogenesis CC during embryonic life, and promotes the formation of Peyer's patch-like CC structures, a major component of the gut-associated lymphoid tissue (By CC similarity). Mediates, through interaction with GDF15-receptor GFRAL, CC GDF15-induced cell-signaling in the brainstem which triggers an CC aversive response, characterized by nausea, vomiting, and/or loss of CC appetite in response to various stresses (PubMed:28846097, CC PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its CC cleavage by caspase in sympathetic neurons and mediates cell migration CC in an integrin (e.g. ITGB1 and ITGB3)-dependent manner CC (PubMed:20702524, PubMed:21357690). Also active in the absence of CC ligand, triggering apoptosis through a mechanism that requires receptor CC intracellular caspase cleavage (PubMed:21357690). Triggers the CC differentiation of rapidly adapting (RA) mechanoreceptors CC (PubMed:20064382). Involved in the development of the neural crest (By CC similarity). Regulates nociceptor survival and size (By similarity). CC Phosphorylates PTK2/FAK1 (PubMed:21454698). CC {ECO:0000250|UniProtKB:P35546, ECO:0000269|PubMed:20064382, CC ECO:0000269|PubMed:20616503, ECO:0000269|PubMed:20702524, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:28846097, ECO:0000269|PubMed:28846099, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:31118272}. CC -!- FUNCTION: [Isoform 1]: Isoform 1 in complex with GFRAL induces higher CC activation of MAPK-signaling pathway than isoform 2 in complex with CC GFRAL. {ECO:0000269|PubMed:28846099}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000269|PubMed:11445581, ECO:0000269|PubMed:25242331, CC ECO:0000269|PubMed:31535977, ECO:0000269|PubMed:9575150}; CC -!- ACTIVITY REGULATION: Repressed by 4-(3-hydroxyanilino)-quinolines CC derivatives, indolin-2-one-derivatives, 2-(alkylsulfanyl)-4-(3-thienyl) CC nicotinonitrile analogs, 3- and 4-substituted beta-carbolin-1-ones, CC vandetanib, motesanib, sorafenib (BAY 43-9006), cabozantinib (XL184), CC lenvatinib, sunitinib, nintedanib, and withaferin A (WA) CC (PubMed:17664273, PubMed:17884497, PubMed:19053769, PubMed:20117004, CC PubMed:20409618, PubMed:20605972, PubMed:21134556, PubMed:29908090, CC PubMed:31118272). Inactivation by sorafenib both reduces kinase CC activity and promotes lysosomal degradation (PubMed:17664273). CC {ECO:0000269|PubMed:17664273, ECO:0000269|PubMed:17884497, CC ECO:0000269|PubMed:19053769, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:20409618, ECO:0000269|PubMed:20605972, CC ECO:0000269|PubMed:21134556, ECO:0000269|PubMed:29908090, CC ECO:0000269|PubMed:31118272}. CC -!- SUBUNIT: Phosphorylated form interacts with the PBT domain of DOK2, CC DOK4 and DOK5 (By similarity). The phosphorylated form interacts with CC PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with CC PTK2/FAK1 (via FERM domain) (PubMed:21454698). Extracellular cell- CC membrane anchored RET cadherin fragments form complex in neurons with CC reduced trophic status, preferentially at the contact sites between CC somas (PubMed:21357690). Interacts with AIP in the pituitary gland; CC this interaction prevents the formation of the AIP-survivin complex CC (PubMed:19366855). Interacts (inactive) with CBLC and CD2AP; CC dissociates upon activation by GDNF which increases CBLC:CD2AP CC interaction (PubMed:18753381). {ECO:0000250|UniProtKB:P35546, CC ECO:0000269|PubMed:18753381, ECO:0000269|PubMed:19366855, CC ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:21454698}. CC -!- INTERACTION: CC P07949; Q9UM73: ALK; NbExp=2; IntAct=EBI-2480756, EBI-357361; CC P07949; P22681: CBL; NbExp=8; IntAct=EBI-2480756, EBI-518228; CC P07949; P62861: FAU; NbExp=4; IntAct=EBI-2480756, EBI-358093; CC P07949; P22455: FGFR4; NbExp=2; IntAct=EBI-2480756, EBI-6256193; CC P07949; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-2480756, EBI-945833; CC P07949; P40763: STAT3; NbExp=3; IntAct=EBI-2480756, EBI-518675; CC P07949; Q9Y490: TLN1; NbExp=2; IntAct=EBI-2480756, EBI-2462036; CC P07949; Q62985: Sh2b1; Xeno; NbExp=3; IntAct=EBI-2480756, EBI-7395583; CC P07949-2; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-4423689, EBI-945833; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19823924, CC ECO:0000269|PubMed:21994944, ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:28953886, ECO:0000269|PubMed:9575150}; Single-pass CC type I membrane protein {ECO:0000269|PubMed:19823924}. Endosome CC membrane {ECO:0000269|PubMed:19823924, ECO:0000269|PubMed:23333276}; CC Single-pass type I membrane protein {ECO:0000269|PubMed:19823924}. CC Note=Predominantly located on the plasma membrane (PubMed:23333276, CC PubMed:9575150). In the presence of SORL1 and GFRA1, directed to CC endosomes (PubMed:23333276). {ECO:0000269|PubMed:23333276, CC ECO:0000269|PubMed:9575150}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=2; CC Name=1; Synonyms=RET51; CC IsoId=P07949-1; Sequence=Displayed; CC Name=2; Synonyms=RET9; CC IsoId=P07949-2; Sequence=VSP_040735; CC -!- INDUCTION: Positively regulated by NKX2-1, PHOX2B, SOX10 and PAX3. CC {ECO:0000269|PubMed:19853745}. CC -!- PTM: Autophosphorylated on C-terminal tyrosine residues upon ligand CC stimulation. {ECO:0000269|PubMed:11061555, ECO:0000269|PubMed:14711813, CC ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, CC ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099}. CC -!- PTM: Proteolytically cleaved by caspase-3. The soluble RET kinase CC fragment is able to induce cell death. The extracellular cell-membrane CC anchored RET cadherin fragment accelerates cell adhesion in sympathetic CC neurons. {ECO:0000269|PubMed:21357690}. CC -!- DISEASE: Hirschsprung disease 1 (HSCR1) [MIM:142623]: A disorder of CC neural crest development characterized by absence of enteric ganglia CC along a variable length of the intestine. It is the most common cause CC of congenital intestinal obstruction. Early symptoms range from CC complete acute neonatal obstruction, characterized by vomiting, CC abdominal distention and failure to pass stool, to chronic constipation CC in the older child. {ECO:0000269|PubMed:10090908, CC ECO:0000269|PubMed:10484767, ECO:0000269|PubMed:10618407, CC ECO:0000269|PubMed:10664228, ECO:0000269|PubMed:10790203, CC ECO:0000269|PubMed:22174939, ECO:0000269|PubMed:7581377, CC ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:7704557, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7997019, CC ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:8114939, CC ECO:0000269|PubMed:9043870, ECO:0000269|PubMed:9090527, CC ECO:0000269|PubMed:9094028, ECO:0000269|PubMed:9174404, CC ECO:0000269|PubMed:9259198, ECO:0000269|PubMed:9384613, CC ECO:0000269|PubMed:9497256, ECO:0000269|Ref.71}. Note=The disease is CC caused by variants affecting the gene represented in this entry. CC -!- DISEASE: Medullary thyroid carcinoma (MTC) [MIM:155240]: Rare tumor CC derived from the C cells of the thyroid. Three hereditary forms are CC known, that are transmitted in an autosomal dominant fashion: (a) CC multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB CC (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC CC cases and where MTC is the only clinical manifestation. CC {ECO:0000269|PubMed:10323403, ECO:0000269|PubMed:10826520, CC ECO:0000269|PubMed:11692159, ECO:0000269|PubMed:24560924, CC ECO:0000269|PubMed:29908090, ECO:0000269|PubMed:31118272, CC ECO:0000269|PubMed:7784092, ECO:0000269|PubMed:7845675, CC ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:8557249, CC ECO:0000269|PubMed:8625130, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9223675, ECO:0000269|PubMed:9259198, CC ECO:0000269|PubMed:9398735, ECO:0000269|PubMed:9452077, CC ECO:0000269|PubMed:9506724, ECO:0000269|PubMed:9621513, CC ECO:0000269|PubMed:9677065}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Multiple neoplasia 2B (MEN2B) [MIM:162300]: Uncommon inherited CC cancer syndrome characterized by predisposition to MTC and CC phaeochromocytoma which is associated with marfanoid habitus, mucosal CC neuromas, skeletal and ophthalmic abnormalities, and ganglioneuromas of CC the intestine tract. Then the disease progresses rapidly with the CC development of metastatic MTC and a pheochromocytome in 50% of cases. CC {ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:7906417, CC ECO:0000269|PubMed:7906866, ECO:0000269|PubMed:7911697, CC ECO:0000269|PubMed:8595427, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9294615, ECO:0000269|PubMed:9360560}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Pheochromocytoma (PCC) [MIM:171300]: A catecholamine-producing CC tumor of chromaffin tissue of the adrenal medulla or sympathetic CC paraganglia. The cardinal symptom, reflecting the increased secretion CC of epinephrine and norepinephrine, is hypertension, which may be CC persistent or intermittent. {ECO:0000269|PubMed:12000816}. Note=Disease CC susceptibility is associated with variants affecting the gene CC represented in this entry. CC -!- DISEASE: Multiple neoplasia 2A (MEN2A) [MIM:171400]: The most frequent CC form of medullary thyroid cancer (MTC). It is an inherited cancer CC syndrome characterized by MTC, phaeochromocytoma and/or CC hyperparathyroidism. {ECO:0000269|PubMed:10522989, CC ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7874109, CC ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, CC ECO:0000269|PubMed:8099202, ECO:0000269|PubMed:8103403, CC ECO:0000269|PubMed:8626834, ECO:0000269|PubMed:8807338, CC ECO:0000269|PubMed:9067749, ECO:0000269|PubMed:9097963, CC ECO:0000269|PubMed:9384613, ECO:0000269|PubMed:9452064}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- DISEASE: Note=Various chromosomal aberrations involving RET are known. CC Some of them have been found in papillary thyroid carcinomas (PTCs) CC (PubMed:10439047, PubMed:10980597, PubMed:12787916, PubMed:2406025). CC Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene CC (PubMed:2406025). Inversion inv(10)(q11.2;q11.2) generates the CC RET/NCOA4 (PTC3) oncogene. Translocation t(10;14)(q11;q32) with GOLGA5 CC generates the RET/GOLGA5 (PTC5) oncogene (PubMed:2734021). CC Translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET CC fusion (PubMed:10980597). Translocation t(6;10)(p21.3;q11.2) with CC TRIM27/RFP generates the Delta RFP/RET oncogene (PubMed:12787916). CC Translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET CC (PTC7) oncogene (PubMed:10439047). Translocation t(7;10)(q32;q11) with CC TRIM24/TIF1 generates the TRIM24/RET (PTC6) oncogene (PubMed:10439047). CC Translocation t(6;10)(p21.3;q11.2) with TRIM27/RFP generates the CC TRIM27/RET oncogene (PubMed:3037315). {ECO:0000269|PubMed:10439047, CC ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:12787916, CC ECO:0000269|PubMed:2406025, ECO:0000269|PubMed:2734021, CC ECO:0000269|PubMed:3037315}. CC -!- DISEASE: Note=Mutations in RET have been detected in patients with CC renal agenesis suggesting a possible involvement of this gene in CC disease pathogenesis. {ECO:0000269|PubMed:18252215}. CC -!- MISCELLANEOUS: Treatment with withaferin A (WA) leads tumor regression CC in medullary thyroid carcinomas (MTC). CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. {ECO:0000255|PROSITE-ProRule:PRU00159}. CC -!- CAUTION: Original thought to be dephosphorylated by PTPRJ on Tyr-905, CC Tyr-1015 and Tyr-1062. However this paper was retracted due to CC manipulation of immunoblot data. {ECO:0000305|PubMed:16778204, CC ECO:0000305|PubMed:30552125}. CC -!- SEQUENCE CAUTION: CC Sequence=AAA36524.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=AAA36786.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAA33787.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC Sequence=CAC14882.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/76/RET"; CC -!- WEB RESOURCE: Name=MEN2 RET database; CC URL="http://www.arup.utah.edu/database/MEN2/MEN2_welcome.php"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AK291807; BAF84496.1; -; mRNA. DR EMBL; AC010864; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC004257; AAH04257.1; -; mRNA. DR EMBL; X15262; CAA33333.1; -; mRNA. DR EMBL; X12949; CAA31408.1; -; mRNA. DR EMBL; M16029; AAA36786.1; ALT_INIT; mRNA. DR EMBL; X15786; CAA33787.1; ALT_INIT; mRNA. DR EMBL; M31213; AAA36524.1; ALT_INIT; mRNA. DR EMBL; AJ297349; CAC14882.1; ALT_INIT; mRNA. DR CCDS; CCDS53525.1; -. [P07949-2] DR CCDS; CCDS7200.1; -. [P07949-1] DR PIR; A27203; TVHURE. DR PIR; A34630; A34630. DR PIR; B34735; B34735. DR PIR; S05582; S05582. DR RefSeq; NP_001393672.1; NM_001406743.1. [P07949-1] DR RefSeq; NP_065681.1; NM_020630.7. [P07949-2] DR RefSeq; NP_066124.1; NM_020975.6. [P07949-1] DR PDB; 2IVS; X-ray; 2.00 A; A/B=705-1013. DR PDB; 2IVT; X-ray; 2.60 A; A=705-1013. DR PDB; 2IVU; X-ray; 2.50 A; A=705-1013. DR PDB; 2IVV; X-ray; 2.25 A; A=705-1013. DR PDB; 2X2K; X-ray; 2.60 A; A=705-1013. DR PDB; 2X2L; X-ray; 2.00 A; A=705-1013. DR PDB; 2X2M; X-ray; 2.50 A; A/B=705-1013. DR PDB; 2X2U; X-ray; 2.00 A; A=29-270. DR PDB; 4CKI; X-ray; 2.12 A; A=705-1013. DR PDB; 4CKJ; X-ray; 1.65 A; A=705-1013. DR PDB; 4UX8; EM; 24.00 A; A/B=29-635. DR PDB; 5AMN; X-ray; 2.57 A; A=705-1012. DR PDB; 5FM2; X-ray; 3.30 A; A=659-1013. DR PDB; 5FM3; X-ray; 2.95 A; A=659-1013. DR PDB; 6FEK; X-ray; 2.30 A; A=705-1013. DR PDB; 6GL7; EM; 6.30 A; E/F=29-635. DR PDB; 6I82; X-ray; 2.05 A; A/B=705-1013. DR PDB; 6I83; X-ray; 1.88 A; A=705-1013. DR PDB; 6NE7; X-ray; 1.99 A; A=705-1013. DR PDB; 6NEC; X-ray; 1.87 A; A/C=705-1013. DR PDB; 6NJA; X-ray; 1.92 A; A=705-1013. DR PDB; 6Q2J; EM; 4.10 A; E/F=29-635. DR PDB; 6Q2N; EM; 4.40 A; E/F=29-635. DR PDB; 6Q2O; EM; 3.65 A; E/F=29-635. DR PDB; 6Q2R; EM; 4.30 A; E/F/Y/Z=29-635. DR PDB; 6Q2S; EM; 3.80 A; E/F=29-635. DR PDB; 6VHG; X-ray; 2.30 A; A=705-1013. DR PDB; 7DU8; X-ray; 2.75 A; A/B=705-1013. DR PDB; 7DU9; X-ray; 2.31 A; A/B=705-1013. DR PDB; 7DUA; X-ray; 1.64 A; A/B=705-1013. DR PDB; 7JU5; X-ray; 1.90 A; A/B=705-1013. DR PDB; 7JU6; X-ray; 2.06 A; A/B=705-1013. DR PDB; 7NZN; X-ray; 2.39 A; A=705-1013. DR PDB; 7RUN; X-ray; 3.51 A; A/B=705-1013. DR PDBsum; 2IVS; -. DR PDBsum; 2IVT; -. DR PDBsum; 2IVU; -. DR PDBsum; 2IVV; -. DR PDBsum; 2X2K; -. DR PDBsum; 2X2L; -. DR PDBsum; 2X2M; -. DR PDBsum; 2X2U; -. DR PDBsum; 4CKI; -. DR PDBsum; 4CKJ; -. DR PDBsum; 4UX8; -. DR PDBsum; 5AMN; -. DR PDBsum; 5FM2; -. DR PDBsum; 5FM3; -. DR PDBsum; 6FEK; -. DR PDBsum; 6GL7; -. DR PDBsum; 6I82; -. DR PDBsum; 6I83; -. DR PDBsum; 6NE7; -. DR PDBsum; 6NEC; -. DR PDBsum; 6NJA; -. DR PDBsum; 6Q2J; -. DR PDBsum; 6Q2N; -. DR PDBsum; 6Q2O; -. DR PDBsum; 6Q2R; -. DR PDBsum; 6Q2S; -. DR PDBsum; 6VHG; -. DR PDBsum; 7DU8; -. DR PDBsum; 7DU9; -. DR PDBsum; 7DUA; -. DR PDBsum; 7JU5; -. DR PDBsum; 7JU6; -. DR PDBsum; 7NZN; -. DR PDBsum; 7RUN; -. DR AlphaFoldDB; P07949; -. DR EMDB; EMD-0026; -. DR EMDB; EMD-11777; -. DR EMDB; EMD-20572; -. DR EMDB; EMD-20575; -. DR EMDB; EMD-20576; -. DR EMDB; EMD-20578; -. DR EMDB; EMD-20579; -. DR EMDB; EMD-2712; -. DR SMR; P07949; -. DR BioGRID; 111911; 272. DR CORUM; P07949; -. DR DIP; DIP-41449N; -. DR FunCoup; P07949; 619. DR IntAct; P07949; 231. DR MINT; P07949; -. DR STRING; 9606.ENSP00000347942; -. DR BindingDB; P07949; -. DR ChEMBL; CHEMBL2041; -. DR DrugBank; DB01809; 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine. DR DrugBank; DB15068; Agerafenib. DR DrugBank; DB12742; Amuvatinib. DR DrugBank; DB08875; Cabozantinib. DR DrugBank; DB12147; Erdafitinib. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB00619; Imatinib. DR DrugBank; DB09078; Lenvatinib. DR DrugBank; DB08901; Ponatinib. DR DrugBank; DB15822; Pralsetinib. DR DrugBank; DB08896; Regorafenib. DR DrugBank; DB15685; Selpercatinib. DR DrugBank; DB06436; Semaxanib. DR DrugBank; DB15036; Sitravatinib. DR DrugBank; DB00398; Sorafenib. DR DrugBank; DB07159; Tamatinib. DR DrugBank; DB05294; Vandetanib. DR DrugBank; DB05014; XL999. DR DrugCentral; P07949; -. DR GuidetoPHARMACOLOGY; 2185; -. DR TCDB; 8.A.23.1.44; the basigin (basigin) family. DR GlyCosmos; P07949; 12 sites, No reported glycans. DR GlyGen; P07949; 19 sites, 4 N-linked glycans (4 sites). DR iPTMnet; P07949; -. DR PhosphoSitePlus; P07949; -. DR BioMuta; RET; -. DR DMDM; 547807; -. DR CPTAC; CPTAC-3059; -. DR jPOST; P07949; -. DR MassIVE; P07949; -. DR PaxDb; 9606-ENSP00000347942; -. DR PeptideAtlas; P07949; -. DR ProteomicsDB; 52047; -. [P07949-1] DR ProteomicsDB; 52048; -. [P07949-2] DR TopDownProteomics; P07949-2; -. [P07949-2] DR Antibodypedia; 1904; 1292 antibodies from 41 providers. DR DNASU; 5979; -. DR Ensembl; ENST00000340058.6; ENSP00000344798.4; ENSG00000165731.23. [P07949-2] DR Ensembl; ENST00000355710.8; ENSP00000347942.3; ENSG00000165731.23. [P07949-1] DR GeneID; 5979; -. DR KEGG; hsa:5979; -. DR MANE-Select; ENST00000355710.8; ENSP00000347942.3; NM_020975.6; NP_066124.1. DR UCSC; uc001jak.2; human. [P07949-1] DR AGR; HGNC:9967; -. DR CIViC; 5979; 1 clinical assertion and 61 evidence items across 114 molecular profiles. DR ClinPGx; PA34335; -. DR CTD; 5979; -. DR DisGeNET; 5979; -. DR GeneCards; RET; -. DR GeneReviews; RET; -. DR HGNC; HGNC:9967; RET. DR HPA; ENSG00000165731; Tissue enhanced (adrenal gland, brain, parathyroid gland). DR MalaCards; RET; -. DR MIM; 114500; phenotype. DR MIM; 142623; phenotype. DR MIM; 155240; phenotype. DR MIM; 162300; phenotype. DR MIM; 164761; gene. DR MIM; 171300; phenotype. DR MIM; 171400; phenotype. DR OpenTargets; ENSG00000165731; -. DR Orphanet; 146; Differentiated thyroid carcinoma. DR Orphanet; 99803; Haddad syndrome. DR Orphanet; 29072; Hereditary pheochromocytoma-paraganglioma. DR Orphanet; 388; Hirschsprung disease. DR Orphanet; 99361; Isolated familial medullary thyroid carcinoma. DR Orphanet; 247698; Multiple endocrine neoplasia type 2A. DR Orphanet; 247709; Multiple endocrine neoplasia type 2B. DR Orphanet; 1848; Renal agenesis, bilateral. DR Orphanet; 93100; Renal agenesis, unilateral. DR Orphanet; 276621; Sporadic pheochromocytoma/secreting paraganglioma. DR VEuPathDB; HostDB:ENSG00000165731; -. DR eggNOG; KOG0200; Eukaryota. DR GeneTree; ENSGT00940000158499; -. DR HOGENOM; CLU_009530_0_0_1; -. DR InParanoid; P07949; -. DR OMA; VENQDPH; -. DR OrthoDB; 4062651at2759; -. DR PAN-GO; P07949; 7 GO annotations based on evolutionary models. DR PhylomeDB; P07949; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; P07949; -. DR Reactome; R-HSA-5673001; RAF/MAP kinase cascade. DR Reactome; R-HSA-8853659; RET signaling. DR Reactome; R-HSA-9768919; NPAS4 regulates expression of target genes. DR Reactome; R-HSA-9830364; Formation of the nephric duct. DR Reactome; R-HSA-9830674; Formation of the ureteric bud. DR SignaLink; P07949; -. DR SIGNOR; P07949; -. DR Agora; ENSG00000165731; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 5979; 18 hits in 1194 CRISPR screens. DR ChiTaRS; RET; human. DR EvolutionaryTrace; P07949; -. DR GeneWiki; RET_proto-oncogene; -. DR GenomeRNAi; 5979; -. DR Pharos; P07949; Tclin. DR PRO; PR:P07949; -. DR Proteomes; UP000005640; Chromosome 10. DR RNAct; P07949; protein. DR Bgee; ENSG00000165731; Expressed in substantia nigra pars reticulata and 130 other cell types or tissues. DR ExpressionAtlas; P07949; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0010008; C:endosome membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB. DR GO; GO:0098797; C:plasma membrane protein complex; IDA:CAFA. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB. DR GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc. DR GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc. DR GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB. DR GO; GO:0007411; P:axon guidance; TAS:Reactome. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL. DR GO; GO:0001838; P:embryonic epithelial tube formation; IEA:Ensembl. DR GO; GO:0048484; P:enteric nervous system development; IEA:Ensembl. DR GO; GO:0160144; P:GDF15-GFRAL signaling pathway; IDA:UniProt. DR GO; GO:0035860; P:glial cell-derived neurotrophic factor receptor signaling pathway; IDA:UniProtKB. DR GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:InterPro. DR GO; GO:0097021; P:lymphocyte migration into lymphoid organs; ISS:UniProtKB. DR GO; GO:0000165; P:MAPK cascade; IEA:Ensembl. DR GO; GO:0033619; P:membrane protein proteolysis; IDA:UniProtKB. DR GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl. DR GO; GO:0007158; P:neuron cell-cell adhesion; IMP:UniProtKB. DR GO; GO:0042551; P:neuron maturation; IEA:Ensembl. DR GO; GO:0061146; P:Peyer's patch morphogenesis; ISS:UniProtKB. DR GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; IDA:UniProtKB. DR GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB. DR GO; GO:0045793; P:positive regulation of cell size; IEA:Ensembl. DR GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:UniProtKB. DR GO; GO:2001241; P:positive regulation of extrinsic apoptotic signaling pathway in absence of ligand; IMP:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl. DR GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB. DR GO; GO:0072300; P:positive regulation of metanephric glomerulus development; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:UniProtKB. DR GO; GO:0007497; P:posterior midgut development; TAS:ProtInc. DR GO; GO:0050770; P:regulation of axonogenesis; IEA:Ensembl. DR GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB. DR GO; GO:0048265; P:response to pain; ISS:UniProtKB. DR GO; GO:0007165; P:signal transduction; TAS:ProtInc. DR GO; GO:0035799; P:ureter maturation; IEA:Ensembl. DR GO; GO:0001657; P:ureteric bud development; IEA:Ensembl. DR CDD; cd11304; Cadherin_repeat; 1. DR CDD; cd05045; PTKc_RET; 1. DR FunFam; 1.10.510.10:FF:000190; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000132; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 2.60.40.60:FF:000205; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR FunFam; 3.30.200.20:FF:000234; Proto-oncogene tyrosine-protein kinase receptor Ret; 1. DR Gene3D; 2.60.40.60; Cadherins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR002126; Cadherin-like_dom. DR InterPro; IPR015919; Cadherin-like_sf. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR041163; Ret_CLD1. DR InterPro; IPR040667; Ret_CLD3. DR InterPro; IPR041317; RET_CLD4. DR InterPro; IPR055162; RET_CRD. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR016249; Tyr_kinase_Ret_rcpt. DR PANTHER; PTHR24416:SF485; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF00028; Cadherin; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR Pfam; PF17756; RET_CLD1; 1. DR Pfam; PF17812; RET_CLD3; 1. DR Pfam; PF17813; RET_CLD4; 1. DR Pfam; PF22540; RET_CRD; 1. DR PIRSF; PIRSF000631; TyrPK_receptor_Ret; 1. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF49313; Cadherin-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50268; CADHERIN_2; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell adhesion; KW Cell membrane; Chromosomal rearrangement; Disease variant; Disulfide bond; KW Endosome; Glycoprotein; Hirschsprung disease; Kinase; Membrane; KW Nucleotide-binding; Phosphoprotein; Proteomics identification; KW Proto-oncogene; Receptor; Reference proteome; Signal; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase. FT SIGNAL 1..28 FT /evidence="ECO:0000255" FT CHAIN 29..1114 FT /note="Proto-oncogene tyrosine-protein kinase receptor Ret" FT /id="PRO_0000024450" FT CHAIN 29..707 FT /note="Extracellular cell-membrane anchored RET cadherin FT 120 kDa fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415292" FT CHAIN 708..1017 FT /note="Soluble RET kinase fragment" FT /evidence="ECO:0000305|PubMed:21357690" FT /id="PRO_0000415293" FT TOPO_DOM 29..635 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 636..657 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 658..1114 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 168..272 FT /note="Cadherin" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00043" FT DOMAIN 724..1016 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 29..153 FT /note="Cadherin-like region 1 (CLD1)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 265..379 FT /note="Cadherin-like region 3 (CLD3)" FT /evidence="ECO:0000305|PubMed:11445581" FT REGION 405..506 FT /note="Cadherin-like region 4 (CLD4)" FT /evidence="ECO:0000305|PubMed:11445581" FT ACT_SITE 874 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 178 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 179 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 230 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 232 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 264 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 265 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 266 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 267 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 268 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 300 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 302 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0000305|PubMed:25242331, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6Q2J" FT BINDING 378 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 564 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 565 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 567 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 569 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 574 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 584 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J" FT BINDING 730..738 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924, ECO:0007744|PDB:4CKI" FT BINDING 758 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000305|PubMed:24560924" FT BINDING 805..807 FT /ligand="semaxanib" FT /ligand_id="ChEBI:CHEBI:91083" FT /ligand_note="inhibitor" FT /evidence="ECO:0000269|PubMed:20117004, FT ECO:0007744|PDB:2X2M" FT SITE 587..588 FT /note="Breakpoint for translocation to form the TRIM27/RET FT oncogene" FT /evidence="ECO:0000269|PubMed:3037315" FT SITE 707..708 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT SITE 712..713 FT /note="Breakpoint for translocation to form PCM1-RET; RET- FT CCDC6; RET-GOLGA5; RET-TRIM24 and RET-TRIM33 oncogenes" FT /evidence="ECO:0000269|PubMed:10439047, FT ECO:0000269|PubMed:10980597, ECO:0000269|PubMed:2406025, FT ECO:0000269|PubMed:2734021" FT SITE 1017..1018 FT /note="Cleavage; by caspase-3" FT /evidence="ECO:0000269|PubMed:21357690" FT MOD_RES 687 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 696 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:19369195" FT MOD_RES 806 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 809 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 826 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 900 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:24560924" FT MOD_RES 905 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:16928683, ECO:0000269|PubMed:20117004, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:28846099" FT MOD_RES 981 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1015 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:24560924" FT MOD_RES 1029 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:24560924" FT MOD_RES 1062 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:11061555, FT ECO:0000269|PubMed:14711813, ECO:0000269|PubMed:24560924, FT ECO:0000269|PubMed:28846099" FT MOD_RES 1090 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT MOD_RES 1096 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000269|PubMed:14711813" FT CARBOHYD 98 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 151 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:20473317" FT CARBOHYD 199 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 336 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 343 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 361 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 367 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 377 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 394 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 448 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 468 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 554 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 688 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000269|PubMed:26237509" FT DISULFID 137..142 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 157..197 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 166..243 FT /evidence="ECO:0000269|PubMed:20473317, FT ECO:0000269|PubMed:25242331, ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:2X2U, ECO:0007744|PDB:4UX8, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 426..430 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 449..478 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6GL7, ECO:0007744|PDB:6Q2J, FT ECO:0007744|PDB:6Q2N, ECO:0007744|PDB:6Q2O, FT ECO:0007744|PDB:6Q2R, ECO:0007744|PDB:6Q2S" FT DISULFID 515..531 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 519..541 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 528..558 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 565..581 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 570..585 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 609..620 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 611..618 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT DISULFID 630..634 FT /evidence="ECO:0000269|PubMed:31535977, FT ECO:0007744|PDB:6Q2J, ECO:0007744|PDB:6Q2N, FT ECO:0007744|PDB:6Q2O, ECO:0007744|PDB:6Q2R, FT ECO:0007744|PDB:6Q2S" FT VAR_SEQ 1064..1114 FT /note="MSDPNWPGESPVPLTRADGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS FT -> RISHAFTRF (in isoform 2)" FT /evidence="ECO:0000303|PubMed:14702039, FT ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:3037315" FT /id="VSP_040735" FT VARIANT 20 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1837067697)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_009459" FT VARIANT 32 FT /note="S -> L (in HSCR1; familial form; dbSNP:rs76764689)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006295" FT VARIANT 40 FT /note="L -> P (in HSCR1; dbSNP:rs2132657920)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:9043870" FT /id="VAR_009492" FT VARIANT 64 FT /note="P -> L (in HSCR1; familial form; dbSNP:rs77596424)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006296" FT VARIANT 67 FT /note="R -> H (in dbSNP:rs192489011)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018153" FT VARIANT 77 FT /note="R -> C (in HSCR1; dbSNP:rs1588862595)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009460" FT VARIANT 93 FT /note="G -> S (in HSCR1; uncertain significance; FT dbSNP:rs1477699803)" FT /evidence="ECO:0000269|PubMed:7633441" FT /id="VAR_006297" FT VARIANT 114 FT /note="R -> C (in HSCR1; uncertain significance; FT dbSNP:rs747483905)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067101" FT VARIANT 114 FT /note="R -> H (in dbSNP:rs76397662)" FT /evidence="ECO:0000269|PubMed:12086152, FT ECO:0000269|PubMed:14566559, ECO:0000269|PubMed:22174939" FT /id="VAR_018154" FT VARIANT 142 FT /note="C -> S (in HSCR1; sporadic form; FT dbSNP:rs2132680131)" FT /id="VAR_006298" FT VARIANT 145 FT /note="V -> G (in HSCR1; also in a colorectal cancer FT sample; somatic mutation; dbSNP:rs1588863999)" FT /evidence="ECO:0000269|PubMed:16959974, FT ECO:0000269|PubMed:22174939" FT /id="VAR_035711" FT VARIANT 155 FT /note="P -> L (in HSCR1; dbSNP:rs999019810)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067102" FT VARIANT 157 FT /note="C -> Y (in HSCR1; uncertain significance; FT dbSNP:rs2132681401)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009461" FT VARIANT 163 FT /note="R -> Q (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs149403911)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041762" FT VARIANT 174 FT /note="F -> S (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009462" FT VARIANT 175 FT /note="R -> P (in HSCR1; dbSNP:rs774097284)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067103" FT VARIANT 180 FT /note="R -> P (in HSCR1; sporadic form; dbSNP:rs370736139)" FT /evidence="ECO:0000269|PubMed:9090527" FT /id="VAR_009463" FT VARIANT 197 FT /note="C -> Y (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:9094028" FT /id="VAR_009464" FT VARIANT 198 FT /note="P -> T (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs76736111)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044392" FT VARIANT 231 FT /note="R -> H (in HSCR1; familial form; dbSNP:rs79661516)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006299" FT VARIANT 251 FT /note="E -> K (in HSCR1; familial form; dbSNP:rs562449603)" FT /evidence="ECO:0000269|PubMed:7581377" FT /id="VAR_006300" FT VARIANT 278 FT /note="T -> A (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067104" FT VARIANT 278 FT /note="T -> N (found in two patients with Hirschsprung FT disease; dbSNP:rs35118262)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041763" FT VARIANT 278 FT /note="T -> P (in HSCR1; dbSNP:rs541929171)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067105" FT VARIANT 287 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1564491460)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006301" FT VARIANT 292 FT /note="V -> M (found in patients with Hirschsprung disease; FT uncertain significance; dbSNP:rs34682185)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:22174939" FT /id="VAR_041764" FT VARIANT 300 FT /note="D -> N (in HSCR1; dbSNP:rs2132719351)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067106" FT VARIANT 313 FT /note="R -> Q (in HSCR1; dbSNP:rs77702891)" FT /evidence="ECO:0000269|PubMed:22174939, FT ECO:0000269|PubMed:9090527" FT /id="VAR_009465" FT VARIANT 316 FT /note="S -> I (in HSCR1; dbSNP:rs1060499894)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067107" FT VARIANT 330 FT /note="R -> Q (in HSCR1; dbSNP:rs80236571)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:8114939" FT /id="VAR_006302" FT VARIANT 339 FT /note="S -> L (in HSCR1; dbSNP:rs774829203)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067108" FT VARIANT 353 FT /note="D -> Y (in HSCR1; dbSNP:rs1837785429)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067109" FT VARIANT 359 FT /note="N -> K (in HSCR1; uncertain significance)" FT /evidence="ECO:0000269|Ref.71" FT /id="VAR_009466" FT VARIANT 360 FT /note="R -> Q (in HSCR1; dbSNP:rs762472027)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067110" FT VARIANT 360 FT /note="R -> W (in HSCR1; dbSNP:rs1424549058)" FT /evidence="ECO:0000269|PubMed:10618407, FT ECO:0000269|PubMed:16959974" FT /id="VAR_009467" FT VARIANT 376 FT /note="V -> A (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044393" FT VARIANT 393 FT /note="F -> L (in HSCR1; familial form; dbSNP:rs78098482)" FT /evidence="ECO:0000269|PubMed:8114939" FT /id="VAR_006303" FT VARIANT 394 FT /note="N -> H (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to FT GDNF)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044394" FT VARIANT 394 FT /note="N -> K (in HSCR1; dbSNP:rs376465385)" FT /evidence="ECO:0000269|PubMed:10618407" FT /id="VAR_009468" FT VARIANT 397 FT /note="V -> M (in HSCR1; dbSNP:rs183729115)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067111" FT VARIANT 399 FT /note="P -> L (in HSCR1; sporadic form; FT dbSNP:rs1554818362)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006304" FT VARIANT 412 FT /note="V -> M (in HSCR1; dbSNP:rs746970700)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067112" FT VARIANT 423 FT /note="G -> R (in HSCR1; dbSNP:rs767601598)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067113" FT VARIANT 432 FT /note="A -> E (found in a patient with congenital central FT hypoventilation syndrome; uncertain significance; FT dbSNP:rs552057730)" FT /evidence="ECO:0000269|PubMed:14566559" FT /id="VAR_018155" FT VARIANT 475 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs138624658)" FT /id="VAR_006305" FT VARIANT 480 FT /note="E -> K (in HSCR1; dbSNP:rs537874538)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067114" FT VARIANT 489 FT /note="D -> N (in dbSNP:rs9282834)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846" FT /id="VAR_018156" FT VARIANT 531 FT /note="C -> CEEC (in MTC; familial form)" FT /evidence="ECO:0000269|PubMed:10323403" FT /id="VAR_009469" FT VARIANT 549..550 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067115" FT VARIANT 593 FT /note="G -> E (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035712" FT VARIANT 595 FT /note="E -> Q (in HSCR1; dbSNP:rs1483605155)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067116" FT VARIANT 600 FT /note="R -> Q (in dbSNP:rs377767393)" FT /evidence="ECO:0000269|PubMed:10612852" FT /id="VAR_008966" FT VARIANT 609 FT /note="C -> G (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009470" FT VARIANT 609 FT /note="C -> R (in MEN2A; dbSNP:rs77558292)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009471" FT VARIANT 609 FT /note="C -> W (in HSCR1; familial form; dbSNP:rs377767396)" FT /evidence="ECO:0000269|PubMed:7881414" FT /id="VAR_006307" FT VARIANT 609 FT /note="C -> Y (in MTC, MEN2A and HSCR1; familial and FT sporadic forms; dbSNP:rs77939446)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7849720, ECO:0000269|PubMed:9384613, FT ECO:0000269|Ref.71" FT /id="VAR_006306" FT VARIANT 611 FT /note="C -> G (in MTC; familial form; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:9677065" FT /id="VAR_009472" FT VARIANT 611 FT /note="C -> R (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009473" FT VARIANT 611 FT /note="C -> S (in MEN2A; dbSNP:rs377767391)" FT /evidence="ECO:0000269|PubMed:8807338" FT /id="VAR_009474" FT VARIANT 611 FT /note="C -> W (in MEN2A and MTC; familial form; FT dbSNP:rs80069458)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006308" FT VARIANT 611 FT /note="C -> Y (in MEN2A; dbSNP:rs377767397)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006309" FT VARIANT 618 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006312" FT VARIANT 618 FT /note="C -> G (in MEN2A; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006310" FT VARIANT 618 FT /note="C -> R (in MEN2A, MTC and HSCR1; dbSNP:rs76262710)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:9259198" FT /id="VAR_006311" FT VARIANT 618 FT /note="C -> S (in MEN2A, HSCR1 and MTC; familial and FT sporadic forms; dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9384613" FT /id="VAR_006313" FT VARIANT 618 FT /note="C -> Y (in MEN2A and MTC; familial form; FT dbSNP:rs79781594)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006314" FT VARIANT 620 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7915165" FT /id="VAR_006318" FT VARIANT 620 FT /note="C -> G (in MEN2A and MTC; familial and sporadic FT forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006315" FT VARIANT 620 FT /note="C -> R (in MEN2A, MTC and HSCR1; familial and FT sporadic forms; dbSNP:rs77316810)" FT /evidence="ECO:0000269|PubMed:7633441, FT ECO:0000269|PubMed:7881414, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8103403, ECO:0000269|PubMed:9090527, FT ECO:0000269|PubMed:9384613, ECO:0000269|Ref.71" FT /id="VAR_006316" FT VARIANT 620 FT /note="C -> S (in MEN2A and MTC; familial form; FT dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:7849720, FT ECO:0000269|PubMed:7860065" FT /id="VAR_006317" FT VARIANT 620 FT /note="C -> W (in MEN2A and HSCR1; dbSNP:rs79890926)" FT /evidence="ECO:0000269|PubMed:9384613" FT /id="VAR_009475" FT VARIANT 620 FT /note="C -> Y (in MEN2A; dbSNP:rs77503355)" FT /evidence="ECO:0000269|PubMed:8103403" FT /id="VAR_006319" FT VARIANT 626 FT /note="Q -> K (in HSCR1; sporadic form; FT dbSNP:rs1255575160)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009476" FT VARIANT 630 FT /note="C -> F (in MEN2A and MTC; familial form; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9067749" FT /id="VAR_006320" FT VARIANT 630 FT /note="C -> S (in MTC; sporadic form; dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009477" FT VARIANT 630 FT /note="C -> Y (in MTC; familial and sporadic forms; FT dbSNP:rs377767405)" FT /evidence="ECO:0000269|PubMed:9223675" FT /id="VAR_009478" FT VARIANT 631 FT /note="D -> G (in thyroid carcinoma; somatic mutation; FT dbSNP:rs121913308)" FT /id="VAR_006321" FT VARIANT 632..634 FT /note="ELC -> DVR (in MEN2A; dbSNP:rs377767408)" FT /evidence="ECO:0000269|PubMed:8099202" FT /id="VAR_006322" FT VARIANT 634..635 FT /note="CR -> WG (in MEN2A)" FT /id="VAR_006329" FT VARIANT 634 FT /note="C -> CHELC (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9097963" FT /id="VAR_009479" FT VARIANT 634 FT /note="C -> F (in MEN2A and pheochromocytoma; FT dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006324" FT VARIANT 634 FT /note="C -> G (in MEN2A and pheochromocytoma; FT dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7915165, ECO:0000269|PubMed:8099202" FT /id="VAR_006323" FT VARIANT 634 FT /note="C -> R (in MEN2A, pheochromocytoma and MTC; familial FT form; also found as somatic mutation in a sporadic thyroid FT carcinoma; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:8103403" FT /id="VAR_006326" FT VARIANT 634 FT /note="C -> S (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75076352)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006327" FT VARIANT 634 FT /note="C -> W (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs77709286)" FT /evidence="ECO:0000269|PubMed:12000816" FT /id="VAR_006328" FT VARIANT 634 FT /note="C -> Y (in MEN2A, pheochromocytoma and MTC; familial FT form; dbSNP:rs75996173)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:7860065, ECO:0000269|PubMed:7915165, FT ECO:0000269|PubMed:8099202" FT /id="VAR_006325" FT VARIANT 636 FT /note="T -> TCRT (in MEN2A)" FT /evidence="ECO:0000269|PubMed:9452064" FT /id="VAR_006330" FT VARIANT 639 FT /note="A -> G (in MTC; sporadic form; dbSNP:rs2132845622)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012743" FT VARIANT 640 FT /note="A -> G (in MEN2A; dbSNP:rs78935588)" FT /evidence="ECO:0000269|PubMed:10522989" FT /id="VAR_009480" FT VARIANT 641 FT /note="A -> G (in MTC; sporadic form)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012744" FT VARIANT 679 FT /note="P -> L (in HSCR1; dbSNP:rs2132851042)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067117" FT VARIANT 690 FT /note="S -> P (in HSCR1; sporadic form)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006331" FT VARIANT 691 FT /note="G -> S (in dbSNP:rs1799939)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:17344846, ECO:0000269|PubMed:9223675, FT ECO:0000269|PubMed:9497256" FT /id="VAR_006332" FT VARIANT 694 FT /note="R -> Q (in HSCR1; dbSNP:rs141185224)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067118" FT VARIANT 730 FT /note="L -> I (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088874" FT VARIANT 730 FT /note="L -> V (confers resistance to vandetanib, FT cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838076782)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088875" FT VARIANT 732 FT /note="E -> K (confers resistance to cabozantinib FT inhibitor)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088876" FT VARIANT 738 FT /note="V -> A (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs2132906265)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088877" FT VARIANT 749 FT /note="R -> T (in dbSNP:rs34288963)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041765" FT VARIANT 762 FT /note="E -> Q (in HSCR1; sporadic form; FT dbSNP:rs2132910256)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_009481" FT VARIANT 765 FT /note="S -> P (in HSCR1; dbSNP:rs75075748)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938, ECO:0000269|PubMed:9043870" FT /id="VAR_009493" FT VARIANT 767 FT /note="S -> R (in HSCR1; sporadic form; FT dbSNP:rs2132928081)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006334" FT VARIANT 768 FT /note="E -> D (in MTC; familial and sporadic forms; FT dbSNP:rs78014899)" FT /evidence="ECO:0000269|PubMed:7784092, FT ECO:0000269|PubMed:7845675, ECO:0000269|PubMed:8807338" FT /id="VAR_006335" FT VARIANT 778 FT /note="V -> I (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; FT dbSNP:rs75686697)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044395" FT VARIANT 783 FT /note="N -> S (in HSCR1; dbSNP:rs587778656)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067119" FT VARIANT 790 FT /note="L -> F (in MEN2A and MTC; familial form; FT dbSNP:rs75030001)" FT /evidence="ECO:0000269|PubMed:9506724" FT /id="VAR_009482" FT VARIANT 791 FT /note="Y -> F (in HSCR1, pheochromocytoma, MTC and MEN2A; FT familial form; dbSNP:rs77724903)" FT /evidence="ECO:0000269|PubMed:12000816, FT ECO:0000269|PubMed:9090527, ECO:0000269|PubMed:9506724" FT /id="VAR_009483" FT VARIANT 804 FT /note="V -> L (in MTC; familial form; confers resistance to FT vandetanib, lenvatinib, cabozantinib and nintedanib FT inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7784092" FT /id="VAR_006336" FT VARIANT 804 FT /note="V -> M (in MTC; familial form; faster FT autophosphorylation and activation, leading to enhanced FT activity; confers resistance to vandetanib, lenvatinib, FT cabozantinib and nintedanib inhibitors; dbSNP:rs79658334)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:9452077" FT /id="VAR_006337" FT VARIANT 806 FT /note="Y -> N (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs1838154415)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088878" FT VARIANT 807 FT /note="A -> V (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs1554819523)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088879" FT VARIANT 810 FT /note="G -> A (found in a patient with lung adenocarcinoma; FT confers resistance to vandetanib inhibitor; FT dbSNP:rs2132943470)" FT /evidence="ECO:0000269|PubMed:31118272" FT /id="VAR_088880" FT VARIANT 810 FT /note="G -> S (confers resistance to vandetanib, FT lenvatinib, cabozantinib and nintedanib inhibitors; FT dbSNP:rs764784013)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088881" FT VARIANT 813 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1318733775)" FT /evidence="ECO:0000269|PubMed:10090908" FT /id="VAR_009484" FT VARIANT 826 FT /note="Y -> S (in dbSNP:rs34617196)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041766" FT VARIANT 830 FT /note="G -> R (in HSCR1; dbSNP:rs200127630)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067120" FT VARIANT 844 FT /note="R -> L (in MTC; familial form; dbSNP:rs55947360)" FT /evidence="ECO:0000269|PubMed:10826520, FT ECO:0000269|PubMed:17344846" FT /id="VAR_011582" FT VARIANT 871 FT /note="V -> I (confers resistance to vandetanib, lenvatinib FT and cabozantinib inhibitors; dbSNP:rs145170911)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088882" FT VARIANT 873 FT /note="R -> Q (in HSCR1; sporadic form; FT dbSNP:rs1451004715)" FT /evidence="ECO:0000269|PubMed:10664228" FT /id="VAR_006338" FT VARIANT 881 FT /note="L -> V (in MTC; confers resistance to nintedanib FT inhibitor; dbSNP:rs377767427)" FT /evidence="ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:31118272" FT /id="VAR_088883" FT VARIANT 883 FT /note="A -> F (in MEN2B; somatic mutation in sporadic FT medullary thyroid carcinoma; requires 2 nucleotide FT substitutions; dbSNP:rs377767429)" FT /evidence="ECO:0000269|PubMed:9294615, FT ECO:0000269|PubMed:9360560" FT /id="VAR_009485" FT VARIANT 891 FT /note="S -> A (in MTC; familial form; dbSNP:rs75234356)" FT /evidence="ECO:0000269|PubMed:9398735" FT /id="VAR_009486" FT VARIANT 893 FT /note="F -> L (in HSCR1; sporadic form; dbSNP:rs768188546 FT and dbSNP:rs2132962164)" FT /evidence="ECO:0000269|PubMed:9174404" FT /id="VAR_006339" FT VARIANT 894 FT /note="G -> S (in a patient with renal agenesis; uncertain FT significance; constitutively phosphorylated; expressed only FT the immature intracellular form; dbSNP:rs2132962245)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044396" FT VARIANT 897 FT /note="R -> Q (in HSCR1; sporadic form; dbSNP:rs76087194)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006340" FT VARIANT 907 FT /note="K -> E (in HSCR1; sporadic form; dbSNP:rs377767430)" FT /evidence="ECO:0000269|PubMed:10790203" FT /id="VAR_006341" FT VARIANT 907 FT /note="K -> T (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067121" FT VARIANT 918 FT /note="M -> T (in MEN2B and MTC; sporadic form; somatic FT mutation; also found in a patient with renal agenesis; FT faster autophosphorylation and activation, leading to FT enhanced activity; dbSNP:rs74799832)" FT /evidence="ECO:0000269|PubMed:18252215, FT ECO:0000269|PubMed:24560924, ECO:0000269|PubMed:29908090, FT ECO:0000269|PubMed:7906417, ECO:0000269|PubMed:7906866, FT ECO:0000269|PubMed:7911697, ECO:0000269|PubMed:8595427, FT ECO:0000269|PubMed:8807338" FT /id="VAR_006342" FT VARIANT 921 FT /note="E -> K (in HSCR1; sporadic form; FT dbSNP:rs2132985306)" FT /evidence="ECO:0000269|PubMed:7997019" FT /id="VAR_006343" FT VARIANT 922 FT /note="S -> F (in MTC; sporadic form; dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:11692159" FT /id="VAR_012745" FT VARIANT 922 FT /note="S -> Y (in dbSNP:rs377767432)" FT /evidence="ECO:0000269|PubMed:8595427" FT /id="VAR_009487" FT VARIANT 946 FT /note="T -> M (in MEN2B and MTC; familial form)" FT /id="VAR_006345" FT VARIANT 961 FT /note="F -> L (in HSCR1)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067122" FT VARIANT 972 FT /note="R -> G (in HSCR1; familial form; dbSNP:rs76534745)" FT /evidence="ECO:0000269|PubMed:7704557, FT ECO:0000269|PubMed:8114938" FT /id="VAR_006346" FT VARIANT 973 FT /note="P -> L (in HSCR1; familial form)" FT /evidence="ECO:0000269|PubMed:7704557" FT /id="VAR_006347" FT VARIANT 980 FT /note="M -> T (in HSCR1; sporadic form)" FT /id="VAR_006348" FT VARIANT 982 FT /note="R -> C (in dbSNP:rs17158558)" FT /evidence="ECO:0000269|PubMed:14566559, FT ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:7633441, ECO:0000269|PubMed:9760196" FT /id="VAR_006349" FT VARIANT 998 FT /note="F -> V (confers resistance to lenvatinib and FT cabozantinib inhibitors; dbSNP:rs2133017302)" FT /evidence="ECO:0000269|PubMed:29908090" FT /id="VAR_088884" FT VARIANT 1039 FT /note="P -> L (in HSCR1; dbSNP:rs79853121)" FT /evidence="ECO:0000269|PubMed:9497256" FT /id="VAR_018157" FT VARIANT 1039 FT /note="P -> Q (in dbSNP:rs79853121)" FT /id="VAR_009488" FT VARIANT 1049 FT /note="P -> L (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs1490712863)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044397" FT VARIANT 1052 FT /note="L -> V (in HSCR1; dbSNP:rs1564501947)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067123" FT VARIANT 1059 FT /note="Missing (in HSCR1)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009489" FT VARIANT 1061 FT /note="L -> P (in HSCR1; dbSNP:rs536486113)" FT /evidence="ECO:0000269|PubMed:10484767, ECO:0000269|Ref.71" FT /id="VAR_009490" FT VARIANT 1062 FT /note="Y -> C (in HSCR1; dbSNP:rs587778659)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_067124" FT VARIANT 1064 FT /note="M -> T (in HSCR1; familial form; dbSNP:rs149513065)" FT /evidence="ECO:0000269|PubMed:22174939" FT /id="VAR_009491" FT VARIANT 1067 FT /note="P -> S (in a patient with renal agenesis; uncertain FT significance; prevents phosphorylation in response to GDNF; FT dbSNP:rs775583354)" FT /evidence="ECO:0000269|PubMed:18252215" FT /id="VAR_044398" FT VARIANT 1112 FT /note="F -> Y (in a bladder transitional cell carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041767" FT MUTAGEN 36 FT /note="Y->S: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 41 FT /note="Y->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 85 FT /note="W->A: Defects in maturation and processing." FT /evidence="ECO:0000269|PubMed:11445581" FT MUTAGEN 707 FT /note="D->N: Impaired cleavage by caspase-3 and loss of FT induced cell death." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 708..1114 FT /note="Missing: Loss of induced cell death, but increased FT cell aggregation." FT /evidence="ECO:0000269|PubMed:21357690" FT MUTAGEN 734 FT /note="E->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 758 FT /note="K->R,M: Loss of kinase activity. No effect on FT interaction with and dissociation from CBLC and CD2AP." FT /evidence="ECO:0000269|PubMed:18753381, FT ECO:0000269|PubMed:21357690, ECO:0000269|PubMed:24560924" FT MUTAGEN 912 FT /note="R->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 913 FT /note="I->A: Enhanced protein autophosphorylation due to FT enhanced substrate presentation in trans." FT /evidence="ECO:0000269|PubMed:24560924" FT MUTAGEN 1062 FT /note="Y->F: Abolishes GFRAL-mediated MAPK1/MAPK2 FT phosphorylation." FT /evidence="ECO:0000269|PubMed:28953886" FT CONFLICT 647 FT /note="I -> V (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT CONFLICT 664 FT /note="A -> S (in Ref. 1; BAF84496)" FT /evidence="ECO:0000305" FT CONFLICT 750 FT /note="A -> G (in Ref. 9; AAA36524)" FT /evidence="ECO:0000305" FT CONFLICT 904 FT /note="S -> P (in Ref. 6; AAA36786)" FT /evidence="ECO:0000305" FT STRAND 30..32 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 34..41 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 49..52 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 70..73 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 75..77 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 79..82 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 85..88 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 90..92 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 94..99 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 103..111 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 120..126 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 139..141 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 142..152 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 157..159 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 162..166 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 174..178 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 184..187 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 191..196 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 202..208 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 212..215 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 222..227 FT /evidence="ECO:0007829|PDB:2X2U" FT TURN 231..233 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 235..245 FT /evidence="ECO:0007829|PDB:2X2U" FT STRAND 252..263 FT /evidence="ECO:0007829|PDB:2X2U" FT HELIX 705..710 FT /evidence="ECO:0007829|PDB:7DUA" FT TURN 715..717 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 721..723 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 724..733 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 736..744 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 746..748 FT /evidence="ECO:0007829|PDB:6NEC" FT STRAND 751..759 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 766..781 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 790..794 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 796..798 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 801..805 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 812..819 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 822..826 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 844..846 FT /evidence="ECO:0007829|PDB:6NJA" FT HELIX 848..867 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 877..879 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 880..883 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 884..886 FT /evidence="ECO:0007829|PDB:7DUA" FT STRAND 887..890 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 893..895 FT /evidence="ECO:0007829|PDB:7JU5" FT TURN 900..902 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 915..917 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 920..925 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 930..945 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 957..959 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 960..965 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 978..987 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 992..994 FT /evidence="ECO:0007829|PDB:7DUA" FT HELIX 998..1010 FT /evidence="ECO:0007829|PDB:7DUA" SQ SEQUENCE 1114 AA; 124319 MW; A3DA0CE01A19A441 CRC64; MAKATSGAAG LRLLLLLLLP LLGKVALGLY FSRDAYWEKL YVDQAAGTPL LYVHALRDAP EEVPSFRLGQ HLYGTYRTRL HENNWICIQE DTGLLYLNRS LDHSSWEKLS VRNRGFPLLT VYLKVFLSPT SLREGECQWP GCARVYFSFF NTSFPACSSL KPRELCFPET RPSFRIRENR PPGTFHQFRL LPVQFLCPNI SVAYRLLEGE GLPFRCAPDS LEVSTRWALD REQREKYELV AVCTVHAGAR EEVVMVPFPV TVYDEDDSAP TFPAGVDTAS AVVEFKRKED TVVATLRVFD ADVVPASGEL VRRYTSTLLP GDTWAQQTFR VEHWPNETSV QANGSFVRAT VHDYRLVLNR NLSISENRTM QLAVLVNDSD FQGPGAGVLL LHFNVSVLPV SLHLPSTYSL SVSRRARRFA QIGKVCVENC QAFSGINVQY KLHSSGANCS TLGVVTSAED TSGILFVNDT KALRRPKCAE LHYMVVATDQ QTSRQAQAQL LVTVEGSYVA EEAGCPLSCA VSKRRLECEE CGGLGSPTGR CEWRQGDGKG ITRNFSTCSP STKTCPDGHC DVVETQDINI CPQDCLRGSI VGGHEPGEPR GIKAGYGTCN CFPEEEKCFC EPEDIQDPLC DELCRTVIAA AVLFSFIVSV LLSAFCIHCY HKFAHKPPIS SAEMTFRRPA QAFPVSYSSS GARRPSLDSM ENQVSVDAFK ILEDPKWEFP RKNLVLGKTL GEGEFGKVVK ATAFHLKGRA GYTTVAVKML KENASPSELR DLLSEFNVLK QVNHPHVIKL YGACSQDGPL LLIVEYAKYG SLRGFLRESR KVGPGYLGSG GSRNSSSLDH PDERALTMGD LISFAWQISQ GMQYLAEMKL VHRDLAARNI LVAEGRKMKI SDFGLSRDVY EEDSYVKRSQ GRIPVKWMAI ESLFDHIYTT QSDVWSFGVL LWEIVTLGGN PYPGIPPERL FNLLKTGHRM ERPDNCSEEM YRLMLQCWKQ EPDKRPVFAD ISKDLEKMMV KRRDYLDLAA STPSDSLIYD DGLSEEETPL VDCNNAPLPR ALPSTWIENK LYGMSDPNWP GESPVPLTRA DGTNTGFPRY PNDSVYANWM LSPSAAKLMD TFDS //